Streptococcus pneumoniae capsular polysaccharide and its conjugate
By developing immunogenic conjugates of streptococcal pneumonia serotype 15B capsal polysaccharide covalently linked to carrier proteins, the problem that existing vaccines cannot effectively protect serotypes 15B, 15A and 15C are solved, and these serums are achieved effective immune response and protective effect.
Patent Information
- Application Number
- CN202011016155.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2014-01-21
- Filing Date
- 2015-01-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2035-02-14
AI Technical Summary
The existing Streptococcus pneumonia vaccine cannot effectively protect children under 2 years of age and certain populations against invasive diseases of serotypes 15B, 15A and 15C, resulting in an increased incidence of invasive pneumococcal diseases caused by these serotypes.
An immunogenic conjugate containing a serotype 15B capsular polysaccharide covalently linked to a carrier protein was developed, and the isolated capsular polysaccharide was obtained through fermentation culture, cleavage, purification and high-pressure homogeneous cutting steps, and conjugated to the CRM197 protein to form an immunogenic composition to provide protection.
The immunogenic composition is able to induce an immune response against serotypes 15B, 15A and 15C, provides effective protection against these serotypes, reduces the risk of infection, and shows significant killing ability in the regulating phagocytosis assay.
Smart Images

Figure CN112336854B_ABST
Abstract
Description
[0001] This application is a divisional application of CN201580005248.X. Technical Field
[0002] The present invention relates to isolated Streptococcus pneumoniae ( Streptococcus pneumoniae ) Serotype 15B capsular polysaccharide and their preparation methods. The present invention also relates to immunogenic conjugates comprising serotype 15B capsular polysaccharide of Streptococcus pneumoniae covalently linked to a carrier protein, their preparation methods and immunogenic compositions and vaccines comprising them. Background Art
[0003] Streptococcus pneumoniae is a Gram-positive, lancet-shaped coccus that usually occurs in pairs (diplococci), but can also occur in short chains or as single cells. They grow easily on blood agar plates, have luminescent colonies and show alpha hemolysis unless cultured anaerobically, in which case they show beta hemolysis. Cells of most pneumococcal serotypes have a capsule, which is a polysaccharide coating surrounding each cell. This capsule is a determinant of virulence in humans, as it interferes with phagocytosis by preventing antibodies from attaching to bacterial cells. More than 90 known pneumococcal capsular serotypes are currently identified, of which the 23 most common serotypes account for approximately 90% of invasive disease worldwide. As a vaccine, the pneumococcal polysaccharide coating confers a reasonable degree of immunity to S. pneumoniae in individuals with a well-developed or uncompromised immune system, while the capsular polysaccharide conjugated to a suitable carrier protein allows immune responses in infants and the elderly, who are also at greatest risk for pneumococcal infection.
[0004] Invasive disease from those seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) has virtually disappeared since the first 7-valent pneumococcal conjugate vaccine (PCV7 or Prevnar) was introduced in 2000. The addition of serotypes 1, 3, 5, 6A, 7F, and 19A to Prevnar 13 has further reduced the number of invasive pneumococcal diseases.
[0005] However, the incidence of invasive pneumococcal disease caused by non-vaccine serotypes (such as S. pneumoniae serotypes 15A, 15B and 15C) has recently increased (see, e.g., Beall B. et al., Journal of Clinical Microbiology. 44(3):999-1017, 2006, or Jacobs et al., Clin Infect Dis. (2008) 47(11):1388-1395). None of the currently commercially available pneumococcal vaccines provide adequate protection against serotype 15B S. pneumoniae in humans and, in particular, in children under 2 years of age. Therefore, there is a need for immunogenic compositions that can be used to induce an immune response against serotype 15B S. pneumoniae. It would also be an additional benefit if such immunogenic compositions could be used to protect subjects from serotypes 15C and / or 15A S. pneumoniae. SUMMARY OF THE INVENTION
[0006] In one aspect, the disclosure provides an isolated S. pneumoniae serotype 15B capsular polysaccharide having a molecular weight of 5 kDa-500 kDa.
[0007] In a further aspect, the disclosure provides an isolated S. pneumoniae serotype 15B capsular polysaccharide comprising at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 mM, preferably at least 0.6 mM acetate per mM of the S. pneumoniae serotype 15B capsular polysaccharide.
[0008] In a further aspect, the disclosure provides an isolated S. pneumoniae serotype 15B capsular polysaccharide comprising at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 mM, preferably at least 0.6 mM glycerol per mM of the S. pneumoniae serotype 15B capsular polysaccharide.
[0009] In a further aspect, the present disclosure provides an immunogenic conjugate comprising an isolated S. pneumoniae serotype 15B capsular polysaccharide disclosed herein covalently linked to a carrier protein. In one aspect, the carrier protein is a CRM 197 .
[0010] In a further aspect, the present disclosure provides an immunogenic composition comprising an immunogenic conjugate disclosed herein and a physiologically acceptable vehicle. In one aspect, the immunogenic composition further comprises at least one additional antigen. In one aspect, the immunogenic composition further comprises an adjuvant.
[0011] In a further aspect, the present disclosure provides a vaccine comprising the immunogenic composition as disclosed herein.
[0012] In a further aspect, the present disclosure provides a method for producing an isolated serotype 15B polysaccharide as disclosed herein, the method comprising the steps of:
[0013] (a) preparing a fermentation culture of Streptococcus pneumoniae serotype 15B bacterial cells;
[0014] (b) lysing bacterial cells in the fermentation culture;
[0015] (c) purifying Streptococcus pneumoniae serotype 15B capsular polysaccharide from a fermentation culture; and,
[0016] (d) S. pneumoniae serotype 15B capsular polysaccharide purified by high pressure homogenization sizing.
[0017] In a further aspect, the present disclosure provides a method for producing an activated S. pneumoniae serotype 15B capsular polysaccharide, the method comprising the step of reacting an isolated S. pneumoniae serotype 15B capsular polysaccharide as disclosed herein with an oxidizing agent. In one aspect, the present disclosure provides an activated serotype 15B capsular polysaccharide obtained or obtainable by the above method.
[0018] In a further aspect, the present disclosure provides a method for preparing an immunogenic conjugate comprising a capsular polysaccharide of Streptococcus pneumoniae serotype 15B covalently linked to a carrier protein, the method comprising the steps of:
[0019] (a) mixing an activated polysaccharide as disclosed herein with a carrier protein;
[0020] (b) reacting the mixed activated polysaccharide and carrier protein with a reducing agent to form a serotype 15B capsular polysaccharide-carrier protein conjugate. In one aspect, the present disclosure provides an immunogenic conjugate obtained or obtainable by the above method.
[0021] In a further aspect, the present disclosure provides a method of protecting a subject from infection by serotype 15B S. pneumoniae, the method comprising administering to the subject an immunogenic amount of an immunogenic composition or vaccine disclosed herein.
[0022] In a further aspect, the present disclosure provides a method of treating or preventing a S. pneumoniae infection, disease or condition associated with serotype 15A, 15B and / or 15C S. pneumoniae in a subject, the method comprising the step of administering a therapeutically or prophylactically effective amount of an immunogenic composition or vaccine disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 —Structure of the repeating unit of the pneumococcal capsular polysaccharide serotype 15B. DETAILED DESCRIPTION OF THE INVENTION
[0024] The present invention can be more easily understood by referring to the detailed description of the following preferred embodiments of the present invention and the examples included herein. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice or test the present invention, some preferred methods and materials are still described herein. In describing embodiments and advocating the present invention, certain terms can be used according to the following definitions.
[0025] definition
[0026] As used herein, the "molecular weight" of a polysaccharide or polypeptide-carrier protein conjugate refers to the molecular weight calculated by size exclusion chromatography (SEC) coupled with a multi-angle laser light scattering detector (MALLS).
[0027] As used herein, the term "free polysaccharide" refers to serotype 15B capsular polysaccharide that is not covalently conjugated to a carrier protein but is present in a serotype 15B capsular polysaccharide-carrier protein conjugate composition. Free polysaccharide may be non-covalently linked (i.e., non-covalently bound, adsorbed, or entrapped in or with) a polysaccharide carrier protein conjugate.
[0028] The percentage of free polysaccharide is measured after final purification of the serotype 15B capsular polysaccharide-carrier protein conjugate. Preferably, it is measured within 4 weeks after final purification. It is expressed as a percentage of the total polysaccharide in the sample.
[0029] As used herein, the term "serotype 15B polysaccharide" or "serotype 15B capsular polysaccharide" refers to the S. pneumoniae serotype 15B capsular polysaccharide.
[0030] As used herein, the term "serotype 15B glycoconjugate" or "serotype 15B conjugate" refers to an isolated serotype 15B polysaccharide covalently conjugated to a carrier protein.
[0031] As used herein, the term "degree of oxidation" (DO) refers to the number of sugar repeating units per aldehyde group generated when an isolated polysaccharide is activated with an oxidizing agent. The degree of oxidation of a polysaccharide can be determined using conventional methods known to those skilled in the art.
[0032] As used herein, the term "subject" refers to a mammal, including humans, or to a bird, fish, reptile, amphibian, or any other animal. The term "subject" also includes household pets or research animals. Non-limiting examples of household pets and research animals include: dogs, cats, pigs, rabbits, rats, mice, gerbils, hamsters, guinea pigs, ferrets, monkeys, birds, snakes, lizards, fish, turtles, and frogs. The term "subject" also includes livestock animals. Non-limiting examples of livestock animals include: alpacas, bison, camels, cattle, deer, pigs, horses, llamas, mules, donkeys, sheep, goats, rabbits, reindeer, yaks, chickens, geese, and turkeys.
[0033] Isolated serotype 15B capsular polysaccharide
[0034] As in Figure 1 As shown in Figure 1, the polysaccharide repeating unit of serotype 15B consists of a branched trisaccharide backbone (one N-acetylglucosamine (Glc p NAc), a galactopyranose (Gal p ) and a pyranose glucose (Glc p )) and connected to Glc p C4 hydroxyl group of NAc Gal p - Gal p The disaccharide branch is composed of phosphoglycerol connected to βGal in the disaccharide branch. p The serotype 15B capsular polysaccharide is O-acetylated and the total amount of O-acetylation is about 0.8 to 0.9 O-acetyl groups per polysaccharide repeat unit (see, e.g., C. Jones et al., Carbohydrate Research , 340 (2005) 403-409). The capsular polysaccharide from serotype 15C has the same backbone structure as serotype 15B but lacks O-acetylation.
[0035] The isolated serotype 15B polysaccharide of the present invention can be obtained by a method comprising the following steps:
[0036] (a) preparing a fermentation culture of serotype 15B Streptococcus pneumoniae bacterial cells;
[0037] (b) lysing bacterial cells in the fermentation culture;
[0038] (c) purifying serotype 15B polysaccharide from the fermentation culture; and,
[0039] (d) Serotype 15B polysaccharide purified by high pressure homogenization.
[0040] Serotype 15B polysaccharides can be obtained directly from bacteria using isolation methods known to those skilled in the art (see, for example, methods disclosed in U.S. Patent Application Publication Nos. 20060228380, 20060228381, 20070184071, 20070184072, 20070231340 and 20080102498 or WO2008118752). In addition, they can be produced using synthetic protocols.
[0041] Serotype 15B S. pneumoniae strains can be obtained from established culture collections (such as, for example, ATCC deposited strain No ATCC10354 or strains available from the Streptococcal Reference Laboratory of the Center for disease control and prevention, Atlanta, GA) or clinical specimens.
[0042] Bacterial cells are preferably grown in a soy-based medium. After fermentation of bacterial cells producing S. pneumoniae serotype 15B, the bacterial cells are lysed to produce cell lysates. Bacterial cells can be lysed using any lysing agent. "Lysing agent" is an agent that helps cell wall rupture and release of autolysins that cause cell lysis, including, for example, detergents. As used herein, the term "detergent" refers to any anionic or cationic detergent that can induce bacterial cell lysis. Representative examples of such detergents for use in the method of the present invention include sodium deoxycholate (DOC), N-lauroylsarcosine, sodium chenodeoxycholate and saponin.
[0043] In one embodiment of the invention, the lysing agent used to lyse bacterial cells is DOC. DOC is the sodium salt of the bile acid deoxycholic acid, which is generally derived from a biological source, such as a cow or bull. DOC activates the LytA protein, which is an autolysin involved in the growth and division of the cell wall of Streptococcus pneumoniae. The LytA protein has a choline binding domain in its C-terminal portion, and mutations in the lytA gene are known to produce LytA mutants that are resistant to DOC lysis.
[0044] In one embodiment of the invention, the lysing agent used to lyse bacterial cells is a lysing agent of non-animal origin. The lysing agent of non-animal origin used in the method of the invention includes agents from non-animal sources that have a similar mode of action to DOC (i.e., the mode of action is to affect LytA function and cause lysis of Streptococcus pneumoniae cells). Such lysing agents of non-animal origin include, but are not limited to, analogs of DOC, surfactants, detergents, and choline structural analogs. In one embodiment, the non-animal derived lytic agent is selected from decanesulfonic acid, tert-octylphenoxypoly(oxyethylene)ethanol (e.g., Igepal® CA-630, CAS#: 9002-93-1, available from Sigma Aldrich, St. Louis, MO), octylphenol ethylene oxide condensate (e.g., Triton X-100, available from Sigma Aldrich, St. Louis, MO), N-lauroylsarcosine, sodium N-lauroylsarcosinate, lauryl iminodipropionic acid, sodium dodecyl sulfate, chenodeoxycholate, hyodeoxycholate, glycodeoxycholate, taurodeoxycholate, taurochenodeoxycholate, and cholate. In another embodiment, the non-animal derived lytic agent is N-lauroylsarcosine. In another embodiment, the lytic agent is sodium N-lauroylsarcosinate.
[0045] Serotype 15B polysaccharide can then be separated from the cell lysate using purification techniques known in the art (including the use of centrifugation, depth filtration, precipitation, ultrafiltration, activated carbon treatment, diafiltration and / or column chromatography) (see, e.g., U.S. Patent Application Publication Nos. 20060228380, 20060228381, 20070184071, 20070184072, 20070231340 and 20080102498 or WO2008118752). The purified serotype 15B capsular polysaccharide can then be used for the preparation of immunogenic conjugates.
[0046] Preferably, in order to generate a conjugate with favorable filterability characteristics and / or yield, tailoring of the polysaccharide to a low molecular weight (MW) range is performed prior to conjugation to a carrier protein. Advantageously, the size of the purified serotype 15B polysaccharide is reduced while retaining key features of the polysaccharide structure, such as, for example, the presence of O-acetyl groups. Preferably, the size of the purified serotype 15B polysaccharide is reduced by mechanical homogenization.
[0047] In a preferred embodiment, the size of the purified serotype 15B polysaccharide is reduced by high pressure homogenization. High pressure homogenization achieves high shear rates by pumping the process stream through a flow path of sufficiently small size. The shear rate is increased by using a greater applied homogenization pressure and the exposure time can be increased by recirculating the feed stream through the homogenizer.
[0048] High pressure homogenization methods are particularly suitable for reducing the size of purified serotype 15B polysaccharides while retaining structural features of the polysaccharide, such as the presence of O-acetyl groups.
[0049] The isolated serotype 15B capsular polysaccharide obtained by purification of serotype 15B polysaccharide from S. pneumoniae lysate and optionally tailoring of the purified polysaccharide can be characterized by different parameters including, for example, molecular weight, mM of glycerol per mM of said serotype 15B capsular polysaccharide, mM of acetate per mM of said serotype 15B capsular polysaccharide.
[0050] The degree of O-acetylation of the polysaccharide can be determined by any method known in the art, for example by proton NMR (see, for example, Lemercinier and Jones (1996) Carbohydrate Research 296; 83-96, Jones and Lemercinier (2002) J. Pharmaceutical and Biomedical Analysis 30; 1233-1247, WO05 / 033148 or WO00 / 56357). Another common method is described in Hestrin (1949) J. Biol. Chem. 180; 249-261. Preferably, the presence of O-acetyl groups is determined by ion HPLC analysis.
[0051] The presence of O-acetyl groups in purified, isolated or activated serotype 15B capsular polysaccharide or in a serotype 15B polysaccharide-carrier protein conjugate is expressed as mM acetate per mM of the polysaccharide or as the number of O-acetyl groups per polysaccharide repeat unit.
[0052] The presence of glycerophosphate side chains can be determined by measuring glycerol using high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) after its release by treating the polysaccharide with hydrofluoric acid (HF). The presence of glycerol in purified isolated or activated serotype 15B capsular polysaccharide or in serotype 15B polysaccharide-carrier protein conjugates is expressed as mM glycerol per mM serotype 15B polysaccharide.
[0053] Isolated serotype 15B capsular polysaccharide may also be produced synthetically using methods known to those skilled in the art.
[0054] In preferred embodiments, the isolated serotype 15B capsular polysaccharide has a molecular weight of 5-500 kDa, 50-500 kDa, 50-450 kDa, 100-400 kDa, 100-350 kDa. In preferred embodiments, the isolated serotype 15B capsular polysaccharide has a molecular weight of 100-350 kDa. In preferred embodiments, the isolated serotype 15B capsular polysaccharide has a molecular weight of 100-300 kDa. In preferred embodiments, the isolated serotype 15B capsular polysaccharide has a molecular weight of 150-300 kDa.
[0055] In preferred embodiments, the isolated serotype 15B capsular polysaccharide comprises at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 mM acetate per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the isolated serotype 15B capsular polysaccharide comprises at least 0.5, 0.6, or 0.7 mM acetate per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the isolated serotype 15B capsular polysaccharide comprises at least 0.6 mM acetate per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the isolated serotype 15B capsular polysaccharide comprises at least 0.7 mM acetate per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the presence of O-acetyl groups is determined by ion-HPLC analysis.
[0056] In preferred embodiments, the isolated serotype 15B capsular polysaccharide comprises at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 mM glycerol per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the isolated serotype 15B capsular polysaccharide comprises at least 0.5, 0.6, or 0.7 mM glycerol per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the isolated serotype 15B capsular polysaccharide comprises at least 0.6 mM glycerol per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the isolated serotype 15B capsular polysaccharide comprises at least 0.7 mM glycerol per mM of the serotype 15B capsular polysaccharide.
[0057] In a preferred embodiment, the isolated serotype 15B capsular polysaccharide has a molecular weight of 100-350 kDa, preferably 150-350 kDa, and comprises at least 0.6 mM acetate per mM of the serotype 15B capsular polysaccharide.
[0058] In a preferred embodiment, the isolated serotype 15B capsular polysaccharide has a molecular weight of 100-350 kDa, preferably 150-350 kDa, and comprises at least 0.6 mM glycerol per mM of the serotype 15B capsular polysaccharide.
[0059] In a preferred embodiment, the isolated serotype 15B capsular polysaccharide comprises at least 0.6 mM acetate per mM of the serotype 15B capsular polysaccharide and at least 0.6 mM glycerol per mM of the serotype 15B capsular polysaccharide.
[0060] In a preferred embodiment, the isolated serotype 15B capsular polysaccharide has a molecular weight of 100-350 kDa, preferably 150-350 kDa, and comprises at least 0.6 mM acetate per mM of the serotype 15B capsular polysaccharide and at least 0.6 mM glycerol per mM of the serotype 15B capsular polysaccharide.
[0061] Serotype 15B capsular polysaccharide-carrier protein conjugate
[0062] The isolated serotype 15B capsular polysaccharide can be conjugated to a carrier protein to obtain an immunogenic conjugate. The isolated polysaccharide can be conjugated to a carrier protein by methods known to those skilled in the art (see, for example, U.S. Patent Application Publication Nos. 20060228380, 20070184071, 20070184072, 20070231340 or WO2011 / 100151).
[0063] In one embodiment, the polysaccharide can be activated with 1-cyano-4-dimethylamino-pyridinium tetrafluoroborate (CDAP) to form a cyanate. The activated polysaccharide can be coupled to the amino group on the carrier protein directly or through a spacer (linker) group. For example, the spacer can be cystamine or cysteamine to provide a thiolated polysaccharide, which can be coupled to the carrier through a thioether bond obtained after reaction with a maleimide-activated carrier protein (e.g., using GMBS) or a haloacetylated carrier protein (e.g., using iodoacetimide or bromoacetic acid N-succinimidyl ester or SIAB, or SIA, or SBAP). Preferably, the cyanate (optionally prepared by CDAP chemistry) is coupled with hexamethylenediamine or adipic acid dihydrazide (ADH), and the amino-derivatized sugar is coupled to the carrier protein through the carboxyl group on the protein carrier using carbodiimide (e.g., EDAC or EDC) chemistry. Such conjugates are described in, for example, WO 93 / 15760, WO 95 / 08348 and WO 96129094.
[0064] Other suitable techniques use carbodiimides, hydrazides, active esters, norbornane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, TSTU. Many are described in International Patent Application Publication No. WO98 / 42721. Coupling can involve a carbonyl linker, which can be formed by reacting the free hydroxyl groups of the sugar with CDI (see Bethell et al., 1979, J. Biol. Chern. 254:2572-4; Hearn et al., 1981, J. Chromatogr. 218:509-18), followed by reaction with the protein to form a carbamate bond. This can involve reduction of the anomeric end to the primary hydroxyl group, optionally, protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling of the CDI carbamate intermediate to the protein amino group.
[0065] In a preferred embodiment, the isolated serotype 15B capsular polysaccharide is conjugated to a carrier protein by reductive amination. Reductive amination involves activation of the polysaccharide by oxidation and conjugation of the activated polysaccharide to the protein carrier by reduction.
[0066] Activation of serotype 15B capsular polysaccharide
[0067] The activated serotype 15B capsular polysaccharide is obtained by reacting the isolated serotype 15B capsular polysaccharide with an oxidizing agent. For example, the activated serotype 15B capsular polysaccharide can be obtained by a method comprising the following steps:
[0068] (a) preparing a fermentation culture of serotype 15B Streptococcus pneumoniae bacterial cells;
[0069] (b) lysing bacterial cells in the fermentation culture;
[0070] (c) purifying serotype 15B polysaccharide from the fermentation culture;
[0071] (d) Serotype 15B polysaccharide purified by high pressure homogenization.
[0072] (e) reacting the tailored serotype 15B polysaccharide with an oxidizing agent.
[0073] In preferred embodiments, the concentration of isolated serotype 15B capsular polysaccharide that is reacted with the oxidizing agent is 0.1-10 mg / mL, 0.5-5 mg / mL, 1-3 mg / mL, or about 2 mg / mL.
[0074] In a preferred embodiment, the oxidizing agent is a periodate. Periodate oxidizes the vicinal hydroxyl group to form a carbonyl or aldehyde group and results in cleavage of the CC bond. The term 'periodate' includes both periodate and periodic acid. The term also includes metaperiodate (IO4- ) also includes orthoperiodate (IO6 5- ). The term 'periodate' also includes various salts of periodate, including sodium periodate and potassium periodate. In a preferred embodiment, the oxidizing agent is sodium periodate. In a preferred embodiment, the periodate used to oxidize the serotype 15B capsular polysaccharide is metaperiodate. In a preferred embodiment, the periodate used to oxidize the serotype 15B capsular polysaccharide is sodium metaperiodate.
[0075] In preferred embodiments, the polysaccharide is reacted with 0.01-10, 0.05-5, 0.1-1, 0.5-1, 0.7-0.8, 0.05-0.5, 0.1-0.3 molar equivalents of oxidant. In preferred embodiments, the polysaccharide is reacted with about 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95 molar equivalents of oxidant. In preferred embodiments, the polysaccharide is reacted with about 0.15 molar equivalents of oxidant. In preferred embodiments, the polysaccharide is reacted with about 0.25 molar equivalents of oxidant. In preferred embodiments, the polysaccharide is reacted with about 0.5 molar equivalents of oxidant. In preferred embodiments, the polysaccharide is reacted with about 0.6 molar equivalents of oxidant. In a preferred embodiment, the polysaccharide is reacted with about 0.7 molar equivalents of the oxidizing agent.
[0076] In preferred embodiments, the duration of the reaction is 1-50, 10-30, 15-20, 15-17 hours, or about 16 hours.
[0077] In preferred embodiments, the temperature of the reaction is maintained at 15-45°C, 15-30°C, 20-25°C. In preferred embodiments, the temperature of the reaction is maintained at about 23°C.
[0078] In a preferred embodiment, the oxidation reaction is carried out in a buffer selected from sodium phosphate, potassium phosphate, 2-(N-morpholino)ethanesulfonic acid (MES) or Bis-Tris. In a preferred embodiment, the buffer is potassium phosphate.
[0079] In preferred embodiments, the buffer has a concentration of 1-500 mM, 1-300 mM, 50-200 mM. In preferred embodiments, the buffer has a concentration of about 100 mM. In preferred embodiments, the oxidation reaction is carried out at a pH of 4-8, 5-7, 5.5 and 6.5. In preferred embodiments, the pH is about 6.
[0080] In a preferred embodiment, the activated serotype 15B capsular polysaccharide is obtained by reacting 0.5-5 mg / mL of isolated serotype 15B capsular polysaccharide with 0.2-0.3 molar equivalents of periodate at a temperature of 20-25°C.
[0081] In a preferred embodiment, the activated serotype 15B capsular polysaccharide is purified. The activated serotype 15B capsular polysaccharide is purified according to methods known to those skilled in the art, such as gel permeation chromatography (GPC), dialysis or ultrafiltration / diafiltration. For example, the activated capsular polysaccharide is concentrated and diafiltered using an ultrafiltration device.
[0082] In a preferred embodiment, the present invention relates to activated serotype 15B capsular polysaccharide obtained or obtainable by the above disclosed method.
[0083] In preferred embodiments, the degree of oxidation of the activated serotype 15B capsular polysaccharide is 2-20, 2-15, 2-10, 2-5, 5-20, 5-15, 5-10, 10-20, 10-15, 15-20. In preferred embodiments, the degree of oxidation of the activated serotype 15B capsular polysaccharide is 2-10, 4-8, 4-6, 6-8, 6-12, 8-12, 9-11, 10-16, 12-16, 14-18, 16-20, 16-18 or 18-20.
[0084] In preferred embodiments, the activated serotype 15B capsular polysaccharide has a molecular weight of 5-500 kDa, 50-500 kDa, 50-450 kDa, 100-400 kDa, 100-350 kDa. In preferred embodiments, the activated serotype 15B capsular polysaccharide has a molecular weight of 100-350 kDa. In preferred embodiments, the activated serotype 15B capsular polysaccharide has a molecular weight of 100-300 kDa. In preferred embodiments, the activated serotype 15B capsular polysaccharide has a molecular weight of 150-300 kDa. In preferred embodiments, the activated serotype 15B capsular polysaccharide has a molecular weight of 100-250 kDa.
[0085] In preferred embodiments, the activated serotype 15B capsular polysaccharide comprises at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 mM acetate per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the activated serotype 15B capsular polysaccharide comprises at least 0.5, 0.6 or 0.7 mM acetate per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the activated serotype 15B capsular polysaccharide comprises at least 0.6 mM acetate per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the activated serotype 15B capsular polysaccharide comprises at least 0.7 mM acetate per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the presence of O-acetyl groups is determined by ion-HPLC analysis.
[0086] In preferred embodiments, the activated serotype 15B capsular polysaccharide comprises at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 mM glycerol per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the activated serotype 15B capsular polysaccharide comprises at least 0.5, 0.6 or 0.7 mM glycerol per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the activated serotype 15B capsular polysaccharide comprises at least 0.6 mM glycerol per mM of the serotype 15B capsular polysaccharide. In preferred embodiments, the activated serotype 15B capsular polysaccharide comprises at least 0.7 mM glycerol per mM of the serotype 15B capsular polysaccharide.
[0087] In a preferred embodiment, the activated serotype 15B capsular polysaccharide has a molecular weight of 100-250 kDa and comprises at least 0.6 mM acetate per mM of the serotype 15B capsular polysaccharide.
[0088] In a preferred embodiment, the activated serotype 15B capsular polysaccharide has a molecular weight of 100-250 kDa and comprises at least 0.6 mM glycerol per mM of the serotype 15B capsular polysaccharide.
[0089] In a preferred embodiment, the activated serotype 15B capsular polysaccharide comprises at least 0.6 mM acetate per mM of the serotype 15B capsular polysaccharide and at least 0.6 mM glycerol per mM of the serotype 15B capsular polysaccharide.
[0090] In a preferred embodiment, the activated serotype 15B capsular polysaccharide has a molecular weight of 100-250 kDa and comprises at least 0.6 mM acetate per mM of the serotype 15B capsular polysaccharide and at least 0.6 mM glycerol per mM of the serotype 15B capsular polysaccharide.
[0091] In an embodiment, the activated serotype 15B capsular polysaccharide is freeze-dried, optionally freeze-dried in the presence of a cryoprotectant / lyoprotectant. In an embodiment, the cryoprotectant / lyoprotectant is a sugar. In a preferred embodiment, the sugar is selected from sucrose, trehalose, raffinose, stachyose, melezitose, dextran, mannitol, lactitol and palatinitol. In a preferred embodiment, the sugar is sucrose. The freeze-dried activated capsular polysaccharide can then be mixed with a solution comprising a carrier protein.
[0092] In another embodiment, the activated serotype 15B capsular polysaccharide is mixed with a carrier protein and lyophilized, optionally in the presence of a cryoprotectant / lyoprotectant. In an embodiment, the cryoprotectant / lyoprotectant is a sugar. In a preferred embodiment, the sugar is selected from sucrose, trehalose, raffinose, stachyose, melezitose, dextran, mannitol, lactitol and palatinitol. In a preferred embodiment, the sugar is sucrose. The co-lyophilized polysaccharide and carrier protein can then be resuspended in a solution and reacted with a reducing agent.
[0093] In an embodiment, the invention relates to lyophilized activated serotype 15B capsular polysaccharide.
[0094] In an embodiment, the present invention relates to co-lyophilized activated serotype 15B capsular polysaccharide and a protein carrier. In a preferred embodiment, the protein carrier is CRM 197 .
[0095] Conjugation of activated serotype 15B capsular polysaccharide and carrier protein
[0096] The activated serotype 15B capsular polysaccharide can be conjugated to a carrier protein by a method comprising the following steps:
[0097] (a) mixing activated serotype 15B capsular polysaccharide and carrier protein, and,
[0098] (b) reacting the mixed activated serotype 15B capsular polysaccharide and carrier protein with a reducing agent to form a serotype 15B capsular polysaccharide-carrier protein conjugate.
[0099] Conjugation of serotype 15B capsular polysaccharide activated by reductive amination in dimethyl sulfoxide (DMSO) and a protein carrier is suitable for maintaining the O-acetyl content of the polysaccharide, compared to, for example, reductive amination in aqueous solution, in which the O-acetylation level of the polysaccharide is significantly reduced. In a preferred embodiment, step (a) and step (b) are carried out in DMSO.
[0100] In a preferred embodiment, step (a) comprises dissolving lyophilized serotype 15B capsular polysaccharide in a solution comprising a carrier protein and DMSO. In a preferred embodiment, step (a) comprises dissolving co-lyophilized serotype 15B capsular polysaccharide and a carrier protein in DMSO.
[0101] When steps (a) and (b) are performed in an aqueous solution, steps (a) and (b) are performed in a buffer at a pH of 6.0-8.5, 7-8 or 7-7.5, preferably selected from PBS, MES, HEPES, Bis-Tris, ADA, PIPES, MOPSO, BES, MOPS, DIPSO, MOBS, HEPPSO, POPSO, TEA, EPPS, Bicine or HEPB. In a preferred embodiment, the buffer is PBS. In a preferred embodiment, the pH is about 7.3.
[0102] In a preferred embodiment, the concentration of activated serotype 15B capsular polysaccharide in step (b) is 0.1-10 mg / mL, 0.5-5 mg / mL, 0.5-2 mg / mL. In a preferred embodiment, the concentration of activated serotype 15B capsular polysaccharide in step (b) is 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 or 3 mg / mL.
[0103] In preferred embodiments, the initial input ratio (weight ratio) of activated serotype 15B capsular polysaccharide to carrier protein is 5:1-0.1:1, 2:1-0.1:1, 2:1-1:1, 1.5:1-1:1, 0.1:1-1:1, 0.3:1-1:1, 0.6:1-1:1.
[0104] In a preferred embodiment, the initial input ratio of activated serotype 15B capsular polysaccharide to carrier protein is about 0.6: 1-1.5: 1, preferably 0.6: 1-1: 1. Such an initial input ratio is particularly suitable for obtaining low levels of free polysaccharide in the immunogenic conjugate.
[0105] In preferred embodiments, the initial input ratio of activated serotype 15B capsular polysaccharide to carrier protein is 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, 1.9:1 or 2:1.
[0106] In embodiments, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride or zinc borohydride in the presence of a Bronsted or Lewis acid, an amine borane (such as pyridine borane, 2-methylpyridine borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMe i PrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In a preferred embodiment, the reducing agent is sodium 2-methylpyridine borane.
[0107] In preferred embodiments, the amount of reducing agent used in step (b) is about 0.1-10 molar equivalents, 0.5-5 molar equivalents, 1-2 molar equivalents. In preferred embodiments, the amount of reducing agent used in step (b) is about 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2 molar equivalents.
[0108] In a preferred embodiment, the duration of step (b) is 1-60 hours, 10-50 hours, 40-50 hours, 42-46 hours. In a preferred embodiment, the duration of step (b) is about 44 hours.
[0109] In a preferred embodiment, the temperature of the reaction in step (b) is maintained at 10-40°C, 15-30°C or 20-26°C. In a preferred embodiment, the temperature of the reaction in step (b) is maintained at about 23°C.
[0110] In a preferred embodiment, the method for preparing an immunogenic conjugate comprising a capsular polysaccharide of Streptococcus pneumoniae serotype 15B covalently linked to a carrier protein further comprises a step of capping (quenching) unreacted aldehyde by adding NaBH4 (step (c)).
[0111] In a preferred embodiment, the amount of NaBH4 used in step (c) is about 0.1-10 molar equivalents, 0.5-5 molar equivalents, 1-3 molar equivalents. In a preferred embodiment, the amount of NaBH4 used in step (c) is about 2 molar equivalents.
[0112] In a preferred embodiment, the duration of step (c) is 0.1-10 hours, 0.5-5 hours, 2-4 hours. In a preferred embodiment, the duration of step (c) is about 3 hours.
[0113] In a preferred embodiment, the temperature of the reaction in step (c) is maintained at 15-45°C, 15-30°C or 20-26°C. In a preferred embodiment, the temperature of the reaction in step (c) is maintained at about 23°C.
[0114] In preferred embodiments, the yield of the conjugation step (step b) is greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90%. In preferred embodiments, the yield of the conjugation step (step b) is greater than 60%. In preferred embodiments, the yield of the conjugation step (step b) is greater than 70%. The yield is the amount of serotype 15B polysaccharide in the conjugate × 100 / the amount of activated polysaccharide used in the conjugation step.
[0115] In a preferred embodiment, the method for preparing an immunogenic conjugate comprising a capsular polysaccharide of Streptococcus pneumoniae serotype 15B covalently linked to a carrier protein comprises the following steps:
[0116] (a) preparing a fermentation culture of serotype 15B Streptococcus pneumoniae bacterial cells;
[0117] (b) lysing bacterial cells in the fermentation culture;
[0118] (c) purifying serotype 15B polysaccharide from the fermentation culture;
[0119] (d) Serotype 15B polysaccharide purified by high pressure homogenization;
[0120] (e) reacting the tailored serotype 15B polysaccharide with an oxidizing agent;
[0121] (f) mixing activated serotype 15B polysaccharide and a carrier protein, and,
[0122] (g) reacting the mixed activated serotype 15B polysaccharide and carrier protein with a reducing agent to form a serotype 15B polysaccharide-carrier protein conjugate; and,
[0123] (h) Unreacted aldehyde is capped (quenched) by the addition of NaBH4.
[0124] In a preferred embodiment, the yield of the conjugation step (step g) of the above method is greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90%. In a preferred embodiment, the yield of the conjugation step (step g) is greater than 60%. In a preferred embodiment, the yield of the conjugation step (step g) is greater than 70%. The yield is (the amount of serotype 15B polysaccharide in the conjugate × 100) / the amount of activated polysaccharide used in the conjugation step.
[0125] After the serotype 15B capsular polysaccharide is conjugated to the carrier protein, the polysaccharide-protein conjugate can be purified (enriched in amount) by various techniques known to those skilled in the art. These techniques include dialysis, concentration / diafiltration procedures, tangential flow filtration, precipitation / elution, column chromatography (DEAE or hydrophobic interaction chromatography) and depth filtration.
[0126] In preferred embodiments, the carrier protein is non-toxic and non-reactive and available in sufficient quantity and purity.The carrier protein should be suitable for standard conjugation procedures.
[0127] In a preferred embodiment, the activated serotype 15B capsular polysaccharide is conjugated to a carrier protein selected from the group consisting of: DT (diphtheria toxin); TT (tetanus toxoid) or fragment C of TT; CRM 197(a non-toxic but antigenically identical variant of diphtheria toxin); other DT point mutants such as CRM176, CRM228, CRM45 (Uchida et al. J. Biol. Chem. 218; 3838-3844, 1973), CRM 9, CRM102, CRM 103 and CRM107 and other mutations described by Nicholls and Youle in Genetically Engineered Toxins, Ed: Frankel, Maecel Dekker Inc, 1992, Glu-148 deletion or mutation to Asp, Gln or Ser and / or Ala 158 to Gly and other mutations described in US 4709017 or US 4950740, mutation of at least one or more residues Lys 516, Lys 526, Phe 530 and / or Lys 534 and US 5917017 or US 6455673, or fragments disclosed in US 5843711; pneumococcal pneumolysin (Kuo et al. (1995) Infect Immun 63; 2706-13) including ply detoxified in some way, such as dPLY-GMBS (WO 04081515, PCT / EP2005 / 010258) or dPLY-formol, PhtX, including PhtA, PhtB, PhtD or PhtE (PhtA, PhtB, PhtD or PhtE sequences disclosed in WO 00 / 37105 or WO 00 / 39299) and fusion proteins of Pht proteins, such as PhtDE fusion protein, PhtBE fusion protein, Pht AE (WO 01 / 98334, WO 03 / 54007, WO2009 / 000826); OMPC (meningococcal outer membrane protein - usually extracted from Neisseria meningitidis serogroup B - EP0372501); PorB (from Neisseria meningitidis); PD (Haemophilus influenzae protein D - see, for example, EP0594610 B), or an immunologically functional equivalent thereof; synthetic peptides (EP0378881, EP0427347); heat shock proteins (WO93 / 17712, WO 94 / 03208); pertussis proteins (WO98 / 58668, EP0471 177); cytokines; lymphokines; growth factors or hormones (WO10 91 / 01146); artificial proteins containing multiple human CD4+ T cell epitopes from antigens of various pathogenic origin (Falugi et al. (2001) Eur J Immunol 31; 3816-3824), such as N19 protein (Baraldoi et al. (2004) Infect Immun 72;4884-7); Pneumococcal surface protein PspA (WO 02 / 091998); Iron uptake protein (WO 01 / 72337); Toxin A or B of Clostridium difficile (WO 00 / 61761). In an embodiment, the activated serotype 15B capsular polysaccharide is conjugated to DT (diphtheria toxoid). In another embodiment, the activated serotype 15B capsular polysaccharide is conjugated to TT (tetanus toxoid). In another embodiment, the activated serotype 15B capsular polysaccharide is conjugated to fragment C of TT. In another embodiment, the activated serotype 15B capsular polysaccharide is conjugated to PD (Haemophilus influenzae protein D - see, for example, EP 0 594 610 B). ;
[0128] In a preferred embodiment, the activated serotype 15B capsular polysaccharide of the present invention is conjugated to a CRM 197 Protein. CRM 197 The protein is a nontoxic form of diphtheria toxin, but is immunogenic in a manner not different from diphtheria toxin. 197 Non-toxigenic phage β197 generated by nitrosoguanidine mutagenesis of toxigenic β-corynebacterial phage (Corynephage beta) tox- Produced by Corynebacterium diphtheriae infection (Uchida, T. et al. 1971, Nature New Biology 233:8-11). CRM was purified by ultrafiltration, ammonium sulfate precipitation and ion exchange chromatography 197 .CRM 197 The protein has the same molecular weight as diphtheria toxin but differs from it by a single base change in the structural gene (guanine to adenine). This single base change results in an amino acid substitution in the mature protein (glycine to glutamic acid) and eliminates the toxicity of diphtheria toxin. CRM 197 Proteins are safe and effective T cell dependent carriers for sugars. About CRM 197 Further details of PTFE and its production can be found in, for example, US 5,614,382.
[0129] In an embodiment, the present invention relates to an immunogenic conjugate comprising a capsular polysaccharide of Streptococcus pneumoniae serotype 15B covalently linked to a carrier protein. In an embodiment, the present invention relates to an immunogenic conjugate comprising a capsular polysaccharide of Streptococcus pneumoniae serotype 15B covalently linked to a carrier protein by reductive amination. In an embodiment, the present invention relates to an immunogenic conjugate comprising a capsular polysaccharide of Streptococcus pneumoniae serotype 15B covalently linked to a carrier protein by reductive amination in DMSO. In a preferred embodiment, the carrier protein is CRM 197In a preferred embodiment, the polysaccharide is an isolated serotype 15B capsular polysaccharide as defined herein. In a preferred embodiment, the polysaccharide is an isolated serotype 15B capsular polysaccharide as defined herein which has been tailored by high pressure homogenisation.
[0130] In preferred embodiments, the immunogenic conjugate comprises less than about 50, 45, 40, 35, 30, 25, 20 or 15% free serotype 15B capsular polysaccharide compared to the total amount of serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises less than about 25% free serotype 15B capsular polysaccharide compared to the total amount of serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises less than about 20% free serotype 15B capsular polysaccharide compared to the total amount of serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises less than about 15% free serotype 15B capsular polysaccharide compared to the total amount of serotype 15B capsular polysaccharide.
[0131] In preferred embodiments, the immunogenic conjugate has a molecular weight of 3000-20000 kDa, 5000-10000 kDa, 5000-20000 kDa, 8000-20000 kDa, 8000-16000 KDa or 10000-16000 KDa. The molecular weight of the immunogenic conjugate is measured by SEC-MALLS.
[0132] In a preferred embodiment, the ratio (weight ratio) of serotype 15B capsular polysaccharide to carrier protein in the conjugate is 0.5-3. In a preferred embodiment, the ratio of serotype 15B capsular polysaccharide to carrier protein in the conjugate is 0.4-2, 0.5-2, 0.5-1.5, 0.5-1, 1-1.5, 1-2. In a preferred embodiment, the ratio of serotype 15B capsular polysaccharide to carrier protein in the conjugate is 0.7-0.9.
[0133] Size Exclusion Chromatography media (CL-4B) can be used to determine the relative molecular size distribution of the conjugates. Size Exclusion Chromatography (SEC) is used in a gravity fed column to analyze the molecular size distribution of the conjugates. Large molecules that are excluded by the pores in the medium elute more rapidly than small molecules. A fraction collector is used to collect the column eluate. Fractions are tested colorimetrically by carbohydrate assay. For the determination of the Kd value, the column is calibrated to establish the fraction (V0) from which the molecules are completely excluded (Kd=0) and which represents the maximum retention (V i ), (Kd=1). The fraction achieved for a specific sample attribute (V e ) through the expression Kd = (V e -V0) / (V i- V0) is related to Kd.
[0134] In preferred embodiments, at least 20% of the immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In preferred embodiments, at least 30% of the immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In preferred embodiments, at least 40% of the immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In preferred embodiments, at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or 85% of the immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In preferred embodiments, at least 60% of the immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In preferred embodiments, at least 70% of the immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column.
[0135] In a preferred embodiment, 40%-90% of the serotype 15B immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In a preferred embodiment, 50%-90% of the serotype 15B immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column. In a preferred embodiment, 65%-80% of the serotype 15B immunogenic conjugates have a Kd of less than or equal to 0.3 in a CL-4B column.
[0136] In preferred embodiments, the immunogenic conjugate comprises at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 mM acetate per mM serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises at least 0.5, 0.6 or 0.7 mM acetate per mM serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises at least 0.6 mM acetate per mM serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises at least 0.7 mM acetate per mM serotype 15B capsular polysaccharide. In preferred embodiments, the presence of O-acetyl groups is determined by ion-HPLC analysis.
[0137] In preferred embodiments, the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the isolated polysaccharide is at least 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9 or 0.95. In preferred embodiments, the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the isolated polysaccharide is at least 0.7. In preferred embodiments, the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the isolated polysaccharide is at least 0.9. In preferred embodiments, the presence of O-acetyl groups is determined by ion-HPLC analysis.
[0138] In preferred embodiments, the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the activated polysaccharide is at least 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9 or 0.95. In preferred embodiments, the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the activated polysaccharide is at least 0.7. In preferred embodiments, the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the activated polysaccharide is at least 0.9. In preferred embodiments, the presence of O-acetyl groups is determined by ion-HPLC analysis.
[0139] In preferred embodiments, the immunogenic conjugate comprises at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 mM glycerol per mM serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises at least 0.5, 0.6 or 0.7 mM glycerol per mM serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises at least 0.6 mM glycerol per mM serotype 15B capsular polysaccharide. In preferred embodiments, the immunogenic conjugate comprises at least 0.7 mM glycerol per mM serotype 15B capsular polysaccharide.
[0140] The degree of conjugation is the number of lysine residues in the carrier protein that are conjugated to the serotype 15B capsular polysaccharide. Evidence of lysine modification of the carrier protein due to covalent attachment to the polysaccharide is obtained by amino acid analysis using conventional methods known to those skilled in the art. 197Protein starting material, conjugation results in a reduction in the number of recovered lysine residues.
[0141] In preferred embodiments, the degree of conjugation of the immunogenic conjugate is 2-15, 2-13, 2-10, 2-8, 2-6, 2-5, 2-4, 3-15, 3-13, 3-10, 3-8, 3-6, 3-5, 3-4, 5-15, 5-10, 8-15, 8-12, 10-15 or 10-12. In preferred embodiments, the degree of conjugation of the immunogenic conjugate is 2-5.
[0142] Immunogenic composition
[0143] The term "immunogenic composition" relates to any pharmaceutical composition containing an antigen (eg, a microorganism or a component thereof), which composition can be used to elicit an immune response in a subject.
[0144] As used herein, "immunogenicity" refers to the ability of an antigen (or an epitope of the antigen) (such as a bacterial capsular polysaccharide) or an immunogenic conjugate or immunogenic composition to elicit a humoral immune response or a cell-mediated immune response, or both, in a host (such as a mammal).
[0145] In embodiments, the disclosure relates to immunogenic compositions comprising the immunogenic serotype 15B capsular polysaccharide-carrier protein conjugates disclosed herein.
[0146] In embodiments, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of binding to serotype 15B S. pneumoniae. In embodiments, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of binding to serotype 15B S. pneumoniae, as measured by a standard ELISA assay.
[0147] In embodiments, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of binding to serotypes 15B and 15A and / or 15C pneumococcus. In embodiments, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of binding to serotypes 15B and 15A and / or 15C pneumococcus as measured by a standard ELISA assay.
[0148] In an embodiment, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of binding to serotypes 15B and 15C pneumococcus. In an embodiment, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of binding to serotypes 15B and 15C pneumococcus as measured by a standard ELISA assay.
[0149] In the ELISA (enzyme-linked immunosorbent assay) method, antibodies from the serum of vaccinated subjects are incubated with polysaccharides that have been adsorbed to a solid support. The bound antibodies are detected with an enzyme-conjugated secondary detection antibody.
[0150] In an embodiment, the ELISA assay is a standardized (WHO) ELISA assay as defined by WHO in 'Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA).' (available at http: / / www.vaccine.uab.edu / ELISA%20protocol.pdf; accessed on March 31, 2014).
[0151] The ELISA measures the type-specific IgG anti-S. pneumoniae capsular polysaccharide (PS) antibodies present in human serum. When dilutions of human serum are added to microtiter plates coated with type-specific capsular PS, antibodies specific for that capsular PS bind to the microtiter plate. Antibodies bound to the plate are labeled with goat anti-human IgG alkaline phosphatase and then detected with p-nitrophenyl phosphate substrate. The optical density of the colored end product is proportional to the amount of anti-capsular PS antibodies present in the serum.
[0152] In embodiments, the immunogenic composition of the invention is capable of eliciting IgG antibodies in humans that are capable of binding to S. pneumoniae serotype 15B polysaccharide at a concentration of at least 0.05, 0.1, 0.2, 0.3, 0.35, 0.4 or 0.5 μg / ml as determined by ELISA assay.
[0153] In embodiments, the immunogenic composition of the invention is capable of eliciting IgG antibodies in humans that are capable of binding to S. pneumoniae serotype 15C polysaccharide at a concentration of at least 0.05, 0.1, 0.2, 0.3, 0.35, 0.4 or 0.5 μg / ml as determined by ELISA assay.
[0154] In embodiments, the immunogenic compositions of the invention are capable of eliciting IgG antibodies in humans that are capable of binding to S. pneumoniae serotype 15B and 15C polysaccharides at a concentration of at least 0.05, 0.1, 0.2, 0.3, 0.35, 0.4 or 0.5 μg / ml as determined by ELISA assay.
[0155] In embodiments, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of killing serotype 15B S. pneumoniae in an opsonophagocytosis assay (OPA) as disclosed herein. In embodiments, the immunogenic compositions disclosed herein, when tested in an OPA assay as disclosed herein, have an OPA titer that is higher than the OPA titer obtained with unconjugated native S. pneumoniae serotype 15B capsular polysaccharide.
[0156] In embodiments, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of killing serotype 15C S. pneumoniae in an opsonophagocytosis assay as disclosed herein. In embodiments, the immunogenic compositions disclosed herein, when tested in an OPA assay as disclosed herein, have an OPA titer that is higher than the OPA titer obtained with unconjugated native S. pneumoniae serotype 15C capsular polysaccharide.
[0157] In embodiments, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of killing serotypes 15B and 15C and / or 15A S. pneumoniae in an opsonophagocytosis assay as disclosed herein.
[0158] In embodiments, the immunogenic compositions disclosed herein, when administered to a subject, induce the formation of antibodies capable of killing serotypes 15B and 15C.
[0159] The pneumococcal opsonophagocytosis assay (OPA), which measures killing of S. pneumoniae cells by phagocytic effector cells in the presence of functional antibodies and complement, is considered an important surrogate for assessing the effectiveness of pneumococcal vaccines.
[0160] The opsonophagocytosis assay (OPA) can be performed by incubating a mixture of S. pneumoniae cells, heat-inactivated human serum to be tested, differentiated HL-60 cells (phagocytes), and an exogenous complement source (e.g., baby rabbit complement). Opsonophagocytosis occurs during the incubation period, and bacterial cells with surface coatings of antibodies and complement are killed under opsonophagocytosis. The colony forming units (cfu) of surviving bacteria that escape from opsonophagocytosis are determined by plating the assay mixture. The OPA titer is defined as the reciprocal dilution that results in a 50% reduction in the number of bacteria relative to the control wells without the test serum. The OPA titer is an interpolation from two dilutions covering this 50% killing cutoff.
[0161] Endpoint titers of 1:8 or higher were considered positive results in these killing type OPAs.
[0162] In embodiments, the immunogenic compositions of the invention are capable of eliciting a titer of at least 1:8 against S. pneumoniae serotype 15B in at least 50% of subjects as determined by an opsonophagocytosis killing assay (OPA). In embodiments, the immunogenic compositions of the invention are capable of eliciting a titer of at least 1:8 against S. pneumoniae serotype 15B in at least 60%, 70%, 80%, 90%, or at least 93% of subjects as determined by an opsonophagocytosis killing assay (OPA).
[0163] In embodiments, the immunogenic composition of the invention is capable of eliciting a titer of at least 1:8 against S. pneumoniae serotype 15C in at least 50% of subjects as determined by an opsonophagocytosis killing assay (OPA). In embodiments, the immunogenic composition of the invention is capable of eliciting a titer of at least 1:8 against S. pneumoniae serotype 15C in at least 60%, 70%, 80%, 90% or at least 95% of subjects as determined by an opsonophagocytosis killing assay (OPA).
[0164] The preparation of the immunogenic composition of the present invention can be achieved using methods recognized in the prior art. For example, the immunogenic conjugate of the present invention can be prepared using a physiologically acceptable vehicle to prepare the composition. Examples of these vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and dextrose solutions.
[0165] In a preferred embodiment, the immunogenic composition may comprise at least one additional antigen. In a preferred embodiment, the immunogenic composition may comprise at least one additional S. pneumoniae capsular polysaccharide.
[0166] In a preferred embodiment, the immunogenic composition may comprise at least one additional S. pneumoniae capsular polysaccharide conjugated to a carrier protein. In a preferred embodiment, the carrier protein is CRM 197 .
[0167] In certain embodiments, the immunogenic composition comprises one or more adjuvants. As defined herein, an "adjuvant" refers to a substance used to enhance the immunogenicity of the immunogenic composition of the invention. Thus, adjuvants are often administered to enhance the immune response, and adjuvants are well known to those skilled in the art. Suitable adjuvants for enhancing the effectiveness of the composition include, but are not limited to:
[0168] (1) Aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.;
[0169] (2) Oil-in-water emulsion formulations (with or without other specific immunostimulants such as muramyl peptides (defined below) or bacterial cell wall components), such as, for example
[0170] (a) MF59 (PCT Publication No. WO 90 / 14837) containing 5% squalene, 0.5% Tween 80 and 0.5% Span 85 (optionally containing varying amounts of MTP-PE (see below), although this is not required)), formulated into submicron particles using a microfluidizer, such as a Model 110Y Microfluidizer (Microfluidics, Newton, MA),
[0171] (b) SAF containing 10% squalene, 0.4% Tween 80, 5% Pluronic block polymer L121, and thr-MDP (see below) was microfluidized to form a submicron emulsion or vortexed to produce an emulsion with larger particle sizes, and
[0172] (c) RiBi™ Adjuvant System (RAS) (Corixa, Hamilton, MT) contains 2% squalene, 0.2% Tween 80, and a 3-O-deacylated monophospholipid A (MPL TM ) (described in U.S. Pat. No. 4,912,094) (Corixa), trehalose dimycolate (TDM), and a cell wall skeleton (CWS), preferably one or more bacterial cell wall components of MPL+CWS (Detox™);
[0173] (3) Saponin adjuvants such as Quil A or STIMULON can be used TM QS-21 (Antigenics, Framingham, MA) (U.S. Pat. No. 5,057,540) or particles thereof such as ISCOMs (immunostimulatory complexes);
[0174] (4) bacterial lipopolysaccharide, synthetic lipid A analogs such as aminoalkyl glucosamine phosphate compounds (AGP), or derivatives or analogs thereof, which are commercially available from Corixa and described in U.S. Pat. No. 6,113,918; one such AGP is 2-[(R)-3-tetradecanoyloxytetradecanoylamino]ethyl 2-deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]-2-[(R)-3-tetradecanoyloxytetradecanoylamino]-bD-glucopyranoside, also known as 529 (formerly RC529), which is formulated in aqueous form or as a stable emulsion, synthetic polynucleotides, such as oligonucleotides containing a CpG motif (U.S. Pat. No. 6,207,646);
[0175] (5) Cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, IL-15, IL-18, etc.), interferons (e.g., interferon-γ), granulocyte macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), tumor necrosis factor (TNF), costimulatory molecules 87-1 and 87-2, etc.;
[0176] (6) detoxified mutants of bacterial ADP-ribosylating toxins, such as wild-type or mutant forms of cholera toxin (CT), e.g. in which glutamic acid at amino acid position 29 is substituted by another amino acid, preferably histidine (according to published international patent application number WO 00 / 18434 (see also WO 02 / 098368 and WO 02 / 098369)); pertussis toxin (PT); or Escherichia coli heat-labile toxin (LT), in particular LT-K63, LT-R72, CT-S109, PT-K9 / G129 (see, e.g. WO 93 / 13302 and WO 92 / 19265); and
[0177] (7) Other substances that act as immunostimulants to enhance the effectiveness of the composition.
[0178] Muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threo-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glyceryl-3-hydroxyphosphoryl)-ethylamine (MTP-PE), and the like.
[0179] In an embodiment of the present invention, the immunogenic composition as disclosed herein comprises a CpG oligonucleotide as an adjuvant. As used herein, a CpG oligonucleotide refers to an immunostimulatory CpG oligodeoxynucleotide (CpG ODN), and therefore, unless otherwise specified, these terms are used interchangeably. An immunostimulatory agent CpG oligodeoxynucleotide contains one or more immunostimulatory CpG motifs, which are non-methylated cytosine-guanine dinucleotides, optionally within certain preferred base backgrounds. The methylation state of a CpG immunostimulatory motif generally refers to a cytosine residue in a dinucleotide. An immunostimulatory oligonucleotide containing at least one non-methylated CpG dinucleotide is an oligonucleotide containing a 5' non-methylated cytosine connected to a 3' guanine by a phosphate bond, and it activates the immune system by binding to Toll-like receptor 9 (TLR-9). In another embodiment, an immunostimulatory oligonucleotide may contain one or more methylated CpG dinucleotides, which will activate the immune system through TLR9 and not as strongly as if the CpG motif is non-methylated. CpG immunostimulatory oligonucleotides may comprise one or more palindromic sequences, which in turn may comprise CpG dinucleotides. CpG oligonucleotides have been described in numerous issued patents, published patent applications, and other publications, including U.S. Pat. Nos. 6,194,388, 6,207,646, 6,214,806, 6,218,371, 6,239,116, and 6,339,068.
[0180] In an embodiment of the invention, the immunogenic composition as disclosed herein comprises any CpG oligonucleotide as described on page 3, line 22 to page 12, line 36 of WO2010 / 125480.
[0181] Different classes of CpG immunostimulatory oligonucleotides have been identified. These are called A, B, C and P classes, and are described in more detail in WO2010 / 125480, page 3, line 22 to page 12, line 36. The methods of the present invention encompass the use of these different classes of CpG immunostimulatory oligonucleotides.
[0182] In an embodiment of the invention, the immunogenic composition as disclosed herein comprises a class A CpG oligonucleotide. Preferably, the "class A" CpG oligonucleotide of the invention has the following nucleic acid sequence: 5' GGGGACGACGTCGTGGGGGGG 3' (SEQ ID NO: 1). Some non-limiting examples of class A oligonucleotides include: 5' G*G*G_G_A_C_G_A_C_G_T_C_G_T_G_G*G*G*G*G*G 3' (SEQ ID NO: 2); wherein * refers to a phosphorothioate bond and - refers to a phosphodiester bond.
[0183] In an embodiment of the invention, the immunogenic composition as disclosed herein comprises a class B CpG oligonucleotide. In one embodiment, the CpG oligonucleotide used in the present invention is a class B CpG oligonucleotide, which is represented by at least the following formula:
[0184] 5'X1X2CGX3X43', wherein X1, X2, X3 and X4 are nucleotides. In one embodiment, X2 is adenine, guanine or thymine. In another embodiment, X3 is cytosine, adenine or thymine.
[0185] The class B CpG oligonucleotide sequences of the present invention are those described extensively in the following patents: U.S. Patent Nos. 6,194,388, 6,207,646, 6,214,806, 6,218,371, 6,239,116 and 6,339,068. Exemplary sequences include, but are not limited to, those disclosed in these later applications and patents.
[0186] In an embodiment, a "class B" CpG oligonucleotide of the invention has the following nucleic acid sequence:
[0187] 5' TCGTCGTTTTTCGGTGCTTTT 3' (SEQ ID NO: 3), or
[0188] 5' TCGTCGTTTTTCGGTCGTTTT 3' (SEQ ID NO: 4), or
[0189] 5' TCGTCGTTTTGTCGTTTTGTCGTT 3' (SEQ ID NO: 5), or
[0190] 5' TCGTCGTTTCGTCGTTTTGTCGTT 3' (SEQ ID NO: 6), or
[0191] 5'TCGTCGTTTTGTCGTTTTTTTCGA 3' (SEQ ID NO: 7).
[0192] In any of these sequences, all bonds may be phosphorothioate bonds. In another embodiment, in any of these sequences, one or more bonds may be phosphodiester, preferably between the "C" and "G" of the CpG motif, forming a semi-flexible CpG oligonucleotide. In any of these sequences, ethyl-uridine or halogen may replace the 5'T; examples of halogen substitutions include, but are not limited to, bromouridine or iodouridine substitutions.
[0193] Some non-limiting examples of class B oligonucleotides include:
[0194] 5' T*C*G*T*C*G*T*T*T*T*T*C*G*G*T*G*C*T*T*T*T 3' (SEQ ID NO: 8), or
[0195] 5' T*C*G*T*C*G*T*T*T*T*T*C*G*G*T*C*G*T*T*T*T 3' (SEQ ID NO: 9), or
[0196] 5' T*C*G*T*C*G*T*T*T*T*G*T*C*G*T*T*T*T*G*T*C*G*T*T 3' (SEQ ID NO:10), or
[0197] 5' T*C*G*T*C*G*T*T*T*C*G*T*C*G*T*T*T*T*G*T*C*G*T*T 3' (SEQ ID NO:11), or
[0198] 5' T*C*G*T*C*G*T*T*T*T*G*T*C*G*T*T*T*T*T*T*T*C*G*A 3' (SEQ ID NO: 12).
[0199] Where * indicates a phosphorothioate bond.
[0200] In an embodiment of the invention, the immunogenic composition as disclosed herein comprises a C-class CpG oligonucleotide. In an embodiment, the "C-class" CpG oligonucleotide of the invention has the following nucleic acid sequence:
[0201] 5' TCGCGTCGTTCGGCGCGCGCCG 3' (SEQ ID NO: 13), or
[0202] 5' TCGTCGACGTTCGGCGCGCGCCG 3' (SEQ ID NO: 14), or
[0203] 5' TCGGACGTTCGGCGCGCGCCG 3' (SEQ ID NO: 15), or
[0204] 5' TCGGACGTTCGGCGCGCCG 3' (SEQ ID NO: 16), or
[0205] 5' TCGCGTCGTTCGGCGCGCCG 3' (SEQ ID NO: 17), or
[0206] 5' TCGACGTTCGGCGCGCGCCG 3' (SEQ ID NO: 18), or
[0207] 5' TCGACGTTCGGCGCGCCG 3' (SEQ ID NO: 19), or
[0208] 5' TCGCGTCGTTCGGCGCCG 3' (SEQ ID NO: 20), or
[0209] 5' TCGCGACGTTCGGCGCGCGCCG 3' (SEQ ID NO: 21), or
[0210] 5' TCGTCGTTTTCGGCGCGCGCCG 3' (SEQ ID NO: 22), or
[0211] 5' TCGTCGTTTTCGGCGGCCGCCG 3' (SEQ ID NO: 23), or
[0212] 5' TCGTCGTTTTACGGCGCCGTGCCG 3' (SEQ ID NO: 24), or
[0213] 5'TCGTCGTTTTCGGCGCGCGCCGT 3' (SEQ ID NO: 25).
[0214] In any of these sequences, all bonds may be phosphorothioate bonds. In another embodiment, in any of these sequences, one or more bonds may be phosphodiester, preferably between the "C" and "G" of the CpG motif, forming a semi-flexible CpG oligonucleotide.
[0215] Some non-limiting examples of class C oligonucleotides include:
[0216] 5' T*C_G*C_G*T*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3' (SEQ ID NO: 26), or
[0217] 5' T*C_G*T*C_G*A*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3' (SEQ ID NO: 27), or
[0218] 5' T*C_G*G*A*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3' (SEQ ID NO: 28), or
[0219] 5' T*C_G*G*A*C_G*T*T*C_G*G*C*G*C*G*C*C*G 3' (SEQ ID NO: 29), or
[0220] 5' T*C_G*C_G*T*C_G*T*T*C_G*G*C*G*C*G*C*C*G 3' (SEQ ID NO: 30), or
[0221] 5' T*C_G*A*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3' (SEQ ID NO: 31), or
[0222] 5' T*C_G*A*C_G*T*T*C_G*G*C*G*C*G*C*C*G 3' (SEQ ID NO: 32), or
[0223] 5' T*C_G*C_G*T*C_G*T*T*C_G*G*C*G*C*C*G 3' (SEQ ID NO: 33), or
[0224] 5' T*C_G*C_G*A*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G 3' (SEQ ID NO: 34), or
[0225] 5' T*C*G*T*C*G*T*T*T*T*C*G*G*C*G*C*G*C*G*C*C*G 3' (SEQ ID NO: 35), or
[0226] 5' T*C*G*T*C*G*T*T*T*T*C*G*G*C*G*G*C*C*G*C*C*G 3' (SEQ ID NO: 36), or
[0227] 5' T*C*G*T*C_G*T*T*T*T*A*C_G*G*C*G*C*C_G*T*G*C*C*G 3' (SEQ ID NO:37), or
[0228] 5' T*C_G*T*C*G*T*T*T*T*C*G*G*C*G*C*G*C*G*C*C*G*T 3' (SEQ ID NO: 38)
[0229] Where * refers to a phosphorothioate bond and _ refers to a phosphodiester bond.
[0230] In any of these sequences, ethyl-uridine or a halogen may be substituted for the 5'T; examples of halogen substitutions include, but are not limited to, bromouridine or iodouridine substitutions.
[0231] In an embodiment of the present invention, the immunogenic composition as disclosed herein comprises a P-class CpG oligonucleotide. In an embodiment, the CpG oligonucleotide used in the present invention is a P-class CpG oligonucleotide, which comprises a 5'TLR activation domain and at least two palindromic regions, a palindromic region is a 5' palindromic region of at least 6 nucleotides in length and is directly or via a spacer connected to a 3' palindromic region of at least 8 nucleotides in length, wherein the oligonucleotide comprises at least one YpR dinucleotide. In an embodiment, the oligonucleotide is not T*C_G*T*C_G*A*C_G*T*T*C_G*G*C*G*C_G*C*G*C*C*G (SEQ ID NO: 27). In one embodiment, the P-class CpG oligonucleotide comprises at least one non-methylated CpG dinucleotide. In another embodiment, the TLR activation domain is TCG, TTCG, TTTCG, TYpR, TTYpR, TTTYpR, UCG, UUCG, UUUCG, TTT or TTTT. In yet another embodiment, the TLR activation domain is within the 5' palindromic region. In another embodiment, the TLR activation domain is immediately 5' to the 5' palindromic region.
[0232] In an embodiment, the "P-class" CpG oligonucleotide of the present invention has the following nucleic acid sequence: 5'TCGTCGACGATCGGCGCGCGCCG 3' (SEQ ID NO: 39).
[0233] In the described sequences, all bonds may be phosphorothioate bonds. In another embodiment, one or more bonds may be phosphodiester, preferably between the "C" and "G" of the CpG motif, forming a semi-flexible CpG oligonucleotide. In any of these sequences, ethyl-uridine or halogen may replace the 5'T: Examples of halogen substitutions include, but are not limited to, bromouridine or iodouridine substitutions.
[0234] Non-limiting examples of P-class oligonucleotides include:
[0235] 5' T*C_G*T*C_G*A*C_G*A*T*C_G*G*C*G*C_G*C*G*C*C*G 3' (SEQ ID NO: 40)
[0236] Where * refers to a phosphorothioate bond and _ refers to a phosphodiester bond.
[0237] In one embodiment, the oligonucleotide comprises at least one phosphorothioate bond. In another embodiment, all internucleotide connections of the oligonucleotide are phosphorothioate bonds. In another embodiment, the oligonucleotide comprises at least one phosphodiester-like bond. In another embodiment, the phosphodiester-like bond is a phosphodiester bond. In another embodiment, a lipophilic group is conjugated to the oligonucleotide. In one embodiment, the lipophilic group is cholesterol.
[0238] In an embodiment, the internucleotide bonds of all CpG oligonucleotides disclosed herein are phosphodiester bonds ("flexible" oligonucleotides, as described in PCT application WO2007 / 026190). In another embodiment, the CpG oligonucleotides of the present invention are resistant to degradation (e.g., stabilized). "Stabilized oligonucleotides" refer to oligonucleotides that are relatively resistant to in vivo degradation (e.g., via exonucleases or endonucleases). Nucleic acid stabilization can be achieved by backbone modifications. Oligonucleotides with phosphorothioate bonds provide maximum activity and protect the oligonucleotide from degradation by intracellular exonucleases and endonucleases. Immunostimulatory oligonucleotides can have chimeric backbones that have a combination of phosphodiester bonds and phosphorothioate bonds. For the purposes of the present invention, a chimeric backbone refers to a partially stabilized backbone in which at least one internucleotide bond is a phosphodiester bond or a phosphodiester-like bond, and in which at least one other internucleotide bond is a stabilized internucleotide bond, wherein the at least one phosphodiester bond or a phosphodiester-like bond and the at least one stabilized bond are different. As described in PCT application WO2007 / 026190, when phosphodiester bonds are preferably located within CpG motifs, such molecules are referred to as "semi-flexible".
[0239] The size of the CpG oligonucleotide (that is, the number of nucleotide residues along the length of the oligonucleotide) can also contribute to the stimulating activity of the oligonucleotide. In order to promote uptake into the cell, the CpG oligonucleotide of the present invention preferably has a minimum length of 6 nucleotide residues. If there are enough immunostimulatory motifs, any size greater than 6 nucleotides (even many kb long) oligonucleotides can induce an immune response because the larger oligonucleotides are degraded in the cell. In certain embodiments, the CpG oligonucleotide is 6-100 nucleotides long, preferably 8-30 nucleotides long. In important embodiments, nucleic acid and oligonucleotide of the present invention are not plasmids or expression vectors.
[0240] In an embodiment, the CpG oligonucleotides disclosed herein comprise substitutions or modifications, such as at the base and / or sugar, as described in paragraphs 134-147 of WO2007 / 026190.
[0241] In embodiments, the CpG oligonucleotide of the present invention is chemically modified. Examples of chemical modifications are known to those skilled in the art and are described in, for example, Uhlmann E. et al. (1990), Chem. Rev. 90:543, S. Agrawal, Ed., Humana Press, Totowa, USA 1993; Crooke, ST et al. (1996) Annu. Rev. Pharmacol. Toxicol. 36:107-129; and Hunziker J. et al., (1995), Mod. Synth. Methods 7:331-417. Oligonucleotides according to the present invention may have one or more modifications, wherein each modification is located at a specific internucleoside phosphodiester bridge and / or at a specific β-D-ribose unit and / or at a specific natural nucleoside base position, compared to oligonucleotides of the same sequence consisting of natural DNA or RNA.
[0242] In some embodiments of the invention, the CpG-containing nucleic acid can simply be mixed with an immunogenic carrier according to methods known to those skilled in the art (see, for example, WO 03 / 024480).
[0243] In a specific embodiment of the present invention, any immunogenic composition disclosed herein comprises 2 μg-100 mg of CpG oligonucleotide, preferably 0.1 mg-50 mg of CpG oligonucleotide, preferably 0.2 mg-10 mg of CpG oligonucleotide, preferably 0.3 mg-5 mg of CpG oligonucleotide, even preferably 0.5-2 mg of CpG oligonucleotide, even preferably 0.75-1.5 mg of CpG oligonucleotide. In a preferred embodiment, the immunogenic composition disclosed herein comprises about 1 mg of CpG oligonucleotide.
[0244] In a preferred embodiment, the adjuvant is an aluminum-based adjuvant selected from aluminum phosphate, aluminum sulfate and aluminum hydroxide. In one embodiment, the immunogenic composition described herein comprises the adjuvant aluminum phosphate.
[0245] In a preferred embodiment, the immunogenic composition of the present invention further comprises at least one of a buffer, a cryoprotectant, a salt, a divalent cation, a non-ionic detergent, a free radical oxidation inhibitor, a diluent or a carrier.
[0246] The immunogenic composition may optionally include one or more physiologically acceptable buffers selected from, but not limited to, Tris (trimethamine), phosphate, acetate, borate, citrate, glycine, histidine, and succinate. In certain embodiments, the formulation is buffered to a pH range of about 5.0 to about 7.0, preferably about 5.5 to about 6.5.
[0247] The immunogenic composition may optionally include one or more nonionic surfactants, including but not limited to polyoxyethylene sorbitan fatty acid esters, polysorbate 80 (Tween 80), polysorbate 60 (Tween 60), polysorbate 40 (Tween 40) and polysorbate-20 (Tween 20), polyoxyethylene alkyl ethers, including but not limited to Brij58, Brij35, and other nonionic surfactants such as Triton X-100, Triton X-114, NP40, Span 85 and Pluronic series (e.g., Pluronic 121). In a preferred embodiment, the immunogenic composition comprises polysorbate 80 or polysorbate 40, preferably polysorbate 80. In a preferred embodiment, the immunogenic composition comprises polysorbate 80 at a concentration of about 0.001% to about 2% (preferably up to about 0.25%) or polysorbate 40 at a concentration of about 0.001% to 1% (preferably up to about 0.5%).
[0248] The present invention also relates to vaccines comprising the immunogenic composition of the present invention.
[0249] Methods for inducing an immune response and protecting against infection
[0250] The present disclosure also includes methods of using the immunogenic compositions described herein.For example, one embodiment of the present disclosure provides a method of inducing an immune response against S. pneumoniae comprising administering to a subject an immunogenic amount of any of the immunogenic compositions described herein.
[0251] One embodiment of the present disclosure provides a method of protecting a subject from infection with Streptococcus pneumoniae, or a method of preventing infection with Streptococcus pneumoniae, or a method of reducing the severity of an infection caused by Streptococcus pneumoniae or delaying the onset of at least one symptom associated with an infection caused by Streptococcus pneumoniae, the method comprising administering to the subject an immunogenic amount of any of the immunogenic compositions described herein.
[0252] One embodiment of the present disclosure provides a method of protecting a subject from infection with serotype 15B Streptococcus pneumoniae, or a method of preventing infection with serotype 15B Streptococcus pneumoniae, or a method of reducing the severity of an infection caused by serotype 15B Streptococcus pneumoniae or delaying the onset of at least one symptom associated with an infection caused by serotype 15B Streptococcus pneumoniae, the method comprising administering to the subject an immunogenic amount of any of the immunogenic compositions described herein.
[0253] One embodiment of the present disclosure provides a method of protecting a subject from infection with serotype 15C pneumococcus, or a method of preventing infection with serotype 15C pneumococcus, or a method of reducing the severity of an infection caused by serotype 15C pneumococcus or delaying the onset of at least one symptom associated with an infection caused by serotype 15C pneumococcus, the method comprising administering to the subject an immunogenic amount of any of the immunogenic compositions described herein.
[0254] One embodiment of the present disclosure provides a method of protecting a subject from infection with serotype 15A pneumococcus, or a method of preventing infection with serotype 15A pneumococcus, or a method of reducing the severity of an infection caused by serotype 15A pneumococcus or delaying the onset of at least one symptom associated with an infection caused by serotype 15A pneumococcus, the method comprising administering to the subject an immunogenic amount of any of the immunogenic compositions described herein.
[0255] One embodiment of the present disclosure provides a method for treating or preventing a S. pneumoniae infection, disease or condition associated with serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B) S. pneumoniae in a subject, the method comprising the step of administering to the subject a therapeutically or prophylactically effective amount of an immunogenic composition as described herein. Another embodiment provides a method for treating or preventing a S. pneumoniae infection, disease or condition associated with serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B) in a subject, the method comprising producing a polyclonal or monoclonal antibody preparation from an immunogenic composition as described herein, and using the antibody preparation to confer passive immunity to the subject.
[0256] In one embodiment, the present disclosure relates to the use of an immunogenic conjugate or immunogenic composition disclosed herein for the preparation of a medicament for protecting a subject from infection with Streptococcus pneumoniae, and / or preventing infection with Streptococcus pneumoniae, and / or reducing the severity of infection caused by Streptococcus pneumoniae or delaying the onset of at least one symptom associated with infection caused by Streptococcus pneumoniae, and / or protecting a subject from serotypes 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B and / or 15C), 5B) pneumococcal infection and / or preventing serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B), and / or reducing the severity of infection or delaying the onset of at least one symptom associated with infection caused by serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B) pneumococcal infection.
[0257] In one embodiment, the present disclosure relates to the use of an immunogenic conjugate or an immunogenic composition disclosed herein for protecting a subject from an infection with Streptococcus pneumoniae, and / or preventing an infection with Streptococcus pneumoniae, and / or reducing the severity of an infection caused by Streptococcus pneumoniae or delaying the onset of at least one symptom associated with an infection caused by Streptococcus pneumoniae, and / or protecting a subject from an infection with serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B) Streptococcus pneumoniae and / or preventing serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B), and / or reducing the severity of an infection caused by serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B) Streptococcus pneumoniae or delaying the onset of at least one symptom associated with an infection caused by serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B) Streptococcus pneumoniae.
[0258] An "immune response" to an immunogenic composition is the development of a humoral immune response and / or a cell-mediated immune response in a subject directed to a molecule present in the immunogenic composition or vaccine composition of interest. For purposes of this disclosure, a "humoral immune response" is an antibody-mediated immune response and involves the induction and generation of antibodies that recognize and bind with some affinity to an antigen in an immunogenic composition or vaccine of the disclosure, while a "cell-mediated immune response" is an immune response mediated by T cells and / or other leukocytes. A "cell-mediated immune response" is triggered by the presentation of antigenic epitopes that bind to class I or class II major histocompatibility complex molecules (MHC), CD1, or other non-classical MHC-like molecules. This activates antigen-specific CD4+ T helper cells or CD8+ cytotoxic T lymphocytes ("CTLs"). CTLs are specific for peptide antigens that are presented in combination with proteins encoded by classical or non-classical MHC and expressed on the cell surface. CTLs help induce and promote the intracellular destruction of intracellular microorganisms, or the lysis of cells infected with such microorganisms. Another aspect of cellular immunity involves antigen-specific responses by helper T cells. Helper T cells act to help stimulate function and focus the activity of non-specific effector cells against cells that display peptides or other antigens bound to classical or non-classical MHC molecules on their surfaces. "Cell-mediated immune response" also refers to the production of cytokines, chemokines, and other such molecules produced by activated T cells and / or other leukocytes (including those derived from CD4+ and CD8+ T cells). The ability of a particular antigen or composition to stimulate a cell-mediated immune response can be determined by a number of assays, such as by lymphocyte proliferation (lymphocyte activation) assays, CTL cytotoxic cell assays, by assaying T lymphocytes specific for antigens in sensitized subjects, or by measuring cytokines produced by T cells in response to antigen restimulation. Such assays are well known in the art. See, for example, Erickson et al. (1993) J. Immunol. 151:4189-4199; and Doe et al. (1994) Eur. J. Immunol. 24:2369-2376.
[0259] As used herein, "treatment" (including variations thereof, e.g., "treat" or "treated") refers to any one or more of: (i) prevention of infection or reinfection, such as in a traditional vaccine, (ii) reduction in severity of symptoms, or elimination of symptoms, and (iii) substantial or complete elimination of the pathogen or condition in question. Thus, treatment can be achieved prophylactically (before infection) or therapeutically (after infection). In the present disclosure, prophylactic treatment is the preferred approach. According to specific embodiments of the present disclosure, compositions and methods are provided for treating (including prophylactic and / or therapeutic immunization) a host animal from infection with serotype 15A, 15B and / or 15C (preferably 15B and / or 15C, more preferably 15B) Streptococcus pneumoniae. The methods of the present disclosure are used to confer prophylactic and / or therapeutic immunity to a subject. The methods of the present disclosure can also be implemented on subjects for biomedical research applications.
[0260] "Immunogenic amount" and "immunologically effective amount" are used interchangeably herein and refer to the amount of an antigen or immunogenic composition that is sufficient to elicit an immune response, i.e., a cellular (T cell) or humoral (B cell or antibody) response, or both, as measured by standard assays known to those of skill in the art.
[0261] In a preferred embodiment, the subject is a human. In a most preferred embodiment, the subject is a newborn (ie, under three months of age), an infant (3 months to one year of age), or a toddler (ie, one to four years of age).
[0262] In embodiments, the immunogenic compositions disclosed herein are used as vaccines.
[0263] In such embodiments, the subject to be vaccinated may be less than 1 year old. For example, the subject to be vaccinated may be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months old. In embodiments, the subject to be vaccinated is about 2, 4 or 6 months old. In another embodiment, the subject to be vaccinated is less than 2 years old. For example, the subject to be vaccinated may be about 12-15 months old. In some cases, as little as one dose of the immunogenic composition according to the present invention is required, but in some cases, a second, third or fourth dose may be given (see Protocol section).
[0264] In an embodiment of the present invention, the subject to be vaccinated is an adult of 50 years of age or older, more preferably an adult of 55 years of age or older. In an embodiment, the subject to be vaccinated is an adult of 65 years of age or older, 70 years of age or older, 75 years of age or older, or 80 years of age or older.
[0265] In an embodiment, the subject to be vaccinated is an immunocompromised individual, particularly a human. An immunocompromised individual is generally defined as a person who exhibits an impaired or reduced ability to mount normal humoral or cellular defenses against attack by infectious agents.
[0266] In embodiments of the invention, the immunocompromised subject to be vaccinated has a disease or condition that compromises the body's immune system and results in an inadequate antibody response to prevent or treat pneumococcal disease.
[0267] In embodiments, the disease is a primary immunodeficiency disorder. Preferably, the primary immunodeficiency disorder is selected from the group consisting of: combined T and B cell immunodeficiency, antibody deficiency, well-defined syndrome, immune dysregulation disease, phagocytic disorder, congenital immunodeficiency, autoinflammatory disorder, and complement deficiency. In embodiments, the primary immunodeficiency disorder is selected from the disorders disclosed on page 24, line 11 - page 25, line 19 of PCT application WO2010 / 125480.
[0268] In a specific embodiment of the invention, the immunocompromised subject to be vaccinated has a disease selected from the group consisting of HIV infection, acquired immune deficiency syndrome (AIDS), cancer, chronic heart or lung disorders, congestive heart failure, diabetes, chronic liver disease, alcoholism, cirrhosis, cerebrospinal fluid leaks, cardiomyopathy, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), spleen dysfunction (such as sickle cell disease), lack of spleen function (asplenia), hematological malignancies, leukemia, multiple myeloma, Hodgkin's disease, lymphoma, renal failure, nephrotic syndrome and asthma.
[0269] In an embodiment of the invention, the immunocompromised subject to be vaccinated suffers from malnutrition.
[0270] In a specific embodiment of the present invention, the immunocompromised subject to be vaccinated is receiving a drug or treatment that reduces the body's resistance to infection. In an embodiment, such a drug is selected from the drugs disclosed on page 26, line 33 to page 26, line 40 of PCT application WO2010 / 125480.
[0271] In a specific embodiment of the invention, the immunocompromised subject to be vaccinated is a smoker.
[0272] In a specific embodiment of the invention, the immunocompromised subject to be vaccinated has a leukocyte count (white blood cell count) of less than 5×10 9 cells / L, or less than 4×10 9 cells / L, or less than 3×10 9 cells / L, or less than 2×109 cells / L, or less than 1×10 9 cells / L, or less than 0.5×10 9 cells / L, or less than 0.3×10 9 cells / L, or less than 0.1×10 9 cells / liter.
[0273] WBC count (leukocyte count): The number of white blood cells (WBC) in the blood. WBC is usually measured as part of a CBC (complete blood count). White blood cells are infection-fighting cells in the blood and are distinct from the red (oxygen-carrying) blood cells called erythrocytes. There are different types of white blood cells, including neutrophils (polymorphonuclear leukocytes; PMNs), band cells (slightly immature neutrophils), T-type lymphocytes (T cells), B-type lymphocytes (B cells), monocytes, eosinophils, and basophils. All types of white blood cells are reflected in the WBC count. The normal range for a white blood cell count is usually 4,300-10,800 cells per cubic millimeter of blood. This may also be called the leukocyte count and may be expressed in international units as 4.3 - 10.8 x 10 9 cells / liter.
[0274] In a specific embodiment of the present invention, the immunocompromised subject to be vaccinated has neutropenia. In a specific embodiment of the present invention, the immunocompromised subject to be vaccinated has a neutrophil count of less than 2×10 9 cells / L, or less than 1×10 9 cells / L, or less than 0.5×10 9 cells / L, or less than 0.1×10 9 cells / L, or less than 0.05×10 9 cells / liter.
[0275] Low white blood cell count or "neutropenia" is a condition characterized by abnormally low levels of neutrophils circulating in the blood. Neutrophils are a specific type of white blood cell that helps prevent and fight infection. The most common reason cancer patients experience neutropenia is as a side effect of chemotherapy. Chemotherapy-induced neutropenia increases a patient's risk of infection and undermines cancer treatment.
[0276] In a specific embodiment of the invention, the immunocompromised subject to be vaccinated has a CD4+ cell count of less than 500 / mm 3 , or CD4+ cell count less than 300 / mm 3 , or CD4+ cell count less than 200 / mm 3, CD4+ cell count less than 100 / mm 3 , CD4+ cell count less than 75 / mm 3 , or CD4+ cell count less than 50 / mm 3 .
[0277] CD4 cell testing is usually reported as mm 3 The normal CD4 count is 500-1600, and the CD8 count is 375-1100. The CD4 count drops dramatically in people with HIV.
[0278] In embodiments of the present invention, any immunocompromised subject disclosed herein is a male human or a female human.
[0279] The amount of conjugate in the composition is generally calculated based on the total polysaccharide conjugated and unconjugated for the conjugate. For example, a conjugate with 20% free polysaccharide will have about 80 µg conjugated polysaccharide and about 20 µg unconjugated polysaccharide in a 100 µg polysaccharide dose. When calculating the dose of the conjugate, the contribution of protein to the conjugate is generally not taken into account. Typically, each dose contains 0.1-100 µg of polysaccharide, particularly 0.1-10 µg, more particularly 1-10 µg, more particularly 1-5 µg. Preferably each dose will contain about 1.1, 2, 2.2, 3, 3.3, 4, 4.4 µg polysaccharide.
[0280] The optimal amounts of the components for a particular immunogenic composition or vaccine can be determined by standard studies involving observation of an appropriate immune response in subjects.After the initial vaccination, the subject may receive one or several booster immunizations at adequate intervals.
[0281] The effectiveness of antigen as an immunogen can be measured as follows, by proliferation assays, or by cytolysis assays (such as chromium release assays that measure the ability of T cells to lyse their specific target cells), or by measuring the level of circulating antibodies specific to the antigen in serum to measure the level of B cell activity. As described herein, immune response can also be detected by measuring the serum level of antigen-specific antibodies induced after the administration of antigens, and more specifically, by measuring the ability of the antibodies so induced to enhance the opsonization phagocytosis of specific white blood cells. The protection level of immune response can be measured by attacking the immune host with the applied antigen. For example, if the antigen to which the immune response is expected to be directed is bacteria, the protection level induced by the immunogenic amount of the antigen is measured by detecting the percentage survival or percentage death after attacking the animal with bacterial cells. In one embodiment, the amount of protection can be measured by measuring at least one symptom associated with bacterial infection (e.g., fever associated with infection). The amount of each antigen in a multi-antigen or multi-component vaccine or immunogenic composition will vary with respect to each other component, and can be determined by methods known to those skilled in the art. Such a method will include a method for measuring immunogenicity and / or in vivo efficacy.
[0282] The present disclosure further provides antibodies and antibody compositions that specifically and selectively bind to the capsular polysaccharide or immunogenic conjugate of the present disclosure. In some embodiments, the antibodies are produced after administering the capsular polysaccharide or immunogenic conjugate of the present disclosure to a subject. In some embodiments, the present disclosure provides purified or isolated antibodies against one or more capsular polysaccharides or immunogenic conjugates of the present disclosure. In some embodiments, the antibodies of the present disclosure are functional as measured by killing bacteria in an animal efficacy model or via an opsonophagocytic killing assay. In some embodiments, the antibodies of the present disclosure confer passive immunity to the subject. The present disclosure also provides polynucleotide molecules encoding antibodies or antibody fragments of the present disclosure, and cells, cell lines (such as hybridoma cells or other engineered cell lines for recombinant production of antibodies), or transgenic animals that produce antibodies or antibody compositions of the present disclosure using techniques well known to those skilled in the art. Example
[0283] Example 1: Preparation of isolated S. pneumoniae serotype 15B capsular polysaccharide
[0284] 1.1 Fermentation and purification
[0285] Serotype 15B capsular polysaccharide can be obtained directly from bacteria using separation methods known to those skilled in the art (see, for example, methods disclosed in U.S. Patent Application Publication Nos. 20060228380, 20060228381, 20070184071, 20070184072, 20070231340 and 20080102498 or WO2008118752). Serotype 15B pneumococcus is grown in a seed bottle and then transferred to a seed fermenter. Once the target optical density is reached, the cells are transferred to a production fermenter. The fermentation broth is inactivated by the addition of N-lauroylsarcosine and purified by ultrafiltration and diafiltration.
[0286] The purified S. pneumoniae serotype 15B polysaccharide was then tailored by high pressure homogenization using a PANDA2K Homogenizer® (GEA Niro Soavi) to produce isolated S. pneumoniae serotype 15B polysaccharide.
[0287] Preferably, the isolated S. pneumoniae serotype 15B capsular polysaccharide obtained by the above method comprises at least 0.6 mM acetate per mM serotype 15B capsular polysaccharide and has a molecular weight of 50 kDa-500 kDa, preferably 150-350 kDa.
[0288] 1.2 Oxidation of isolated S. pneumoniae serotype 15B capsular polysaccharide
[0289] Polysaccharide oxidation was performed in 100 mM potassium phosphate buffer (pH 6.0 ± 0.2) by sequentially adding calculated amounts of 500 mM potassium phosphate buffer (pH 6.0) and WFI to obtain a final polysaccharide concentration of 2.0 g / L. If necessary, the reaction pH was adjusted to about pH 6.0. After pH adjustment, the reaction temperature was adjusted to 23 ± 2 °C. The oxidation reaction was started by adding about 0.25 molar equivalents of sodium periodate. The oxidation reaction process was carried out at 23 ± 2 °C for about 16 hours.
[0290] Concentration and diafiltration of the activated polysaccharide were performed using a 10K MWCO ultrafiltration cassette. Diafiltration was performed against 20 diafiltration volumes of WFI. The purified activated polysaccharide was then stored at 5±3°C. The purified activated polysaccharide was characterized inter alia by: (i) sugar concentration by colorimetric determination; (ii) aldehyde concentration by colorimetric determination; (iii) degree of oxidation (iv) molecular weight by SEC-MALLS and (v) presence of O-acetyl groups and glycerol.
[0291] SEC-MALLS is used to determine the molecular weight of polysaccharides and polysaccharide-protein conjugates. Polysaccharides are separated by hydrodynamic volume using SEC. Molecular weight is determined using refractive index (RI) and multi-angle laser light scattering (MALLS) detectors. When light interacts with a substance, it scatters and the amount of scattered light is related to the concentration of the substance, dn / dc squared (specific refractive index increment), and the molar mass. The molecular weight measurement is calculated based on the readings of the light signal scattered from the MALLS detector and the concentration signal from the RI detector.
[0292] The degree of oxidation of the activated polysaccharide (DO = moles of sugar repeating units / moles of aldehyde) was determined as follows:
[0293] The number of moles of sugar repeating units is determined by various colorimetric methods, for example by using the anthrone method. By the anthrone method, polysaccharides are first decomposed into monosaccharides by the action of sulfuric acid and heat. The anthrone reagent reacts with the hexoses to form a yellow-green colored complex, the absorbance of which is read spectrophotometrically at 625 nm. Within the range of the assay, the absorbance is proportional to the amount of hexoses present.
[0294] The MBTH colorimetric method is also used to determine the number of moles of aldehyde. The MBTH assay involves the formation of an azine compound by reacting an aldehyde group (from a given sample) with 3-methyl-2-benzothiazolone hydrazone (MBTH assay reagent). Excess 3-methyl-2-benzothiazolone hydrazone is oxidized to form an active cation. The active cation reacts with the azine to form a blue chromophore. The chromophore formed is then read spectrally at 650nm.
[0295] Preferably, the activated S. pneumoniae serotype 15B capsular polysaccharide obtained by the above method comprises at least 0.6 mM acetate per mM serotype 15B capsular polysaccharide and has a molecular weight of 50 kDa-500 kDa, preferably 100-250 kDa.
[0296] 1.3 Activated S. pneumoniae serotype 15B capsular polysaccharide and CRM 197 Conjugation
[0297] The conjugation method consists of the following steps:
[0298] a) Mixed with sucrose excipient and freeze-dried
[0299] b) Reconstitution of lyophilized activated polysaccharides and CRMs 197
[0300] c) Conjugation of activated polysaccharides to CRM 197 And add cap
[0301] d) Purification of the conjugate
[0302] a) Mixed with sucrose excipient and freeze-dried
[0303] The activated polysaccharide was mixed with sucrose to a ratio of 25 g sucrose per gram of activated polysaccharide. The mixed mixture was then lyophilized in the vial. After lyophilization, the vial containing the lyophilized activated polysaccharide was stored at -20 ± 5°C. Calculation of the amount of CRM 197 The proteins were separated, shell-frozen and lyophilized. 197 Store at -20±5℃.
[0304] b) Reconstitution of lyophilized activated polysaccharides and CRMs 197 protein
[0305] The lyophilized activated polysaccharide was reconstituted in anhydrous dimethyl sulfoxide (DMSO). Once the polysaccharide was completely dissolved, an equal amount of anhydrous DMSO was added to the lyophilized CRM. 197 Used for refactoring.
[0306] c) Conjugation and capping
[0307] Reconstructed activated polysaccharides and reconstructed CRM 197 Combine in a reaction vessel (input ratio 0.8:1), then mix thoroughly to obtain a clear solution, and then initiate conjugation with sodium cyanoborohydride. The final polysaccharide concentration in the reaction solution is about 1 g / L. Conjugation is initiated by adding 1.0 – 1.5 MEq of sodium cyanoborohydride to the reaction mixture and incubate at 23±2°C for 40-48 hours. The conjugation reaction is terminated by adding 2 MEq of sodium borohydride (NaBH4) to cap the unreacted aldehyde groups. This capping reaction continues at 23±2°C for 3±1 hours.
[0308] d) Purification of the conjugate
[0309] The conjugate solution was diluted 1:10 with cooled 5 mM succinate-0.9% saline (pH 6.0) to prepare for purification by tangential flow filtration using a 100-300K MWCO filter membrane. The diluted conjugate solution was filtered through a 5 μm filter and diafiltered using 5 mM succinate-0.9% saline (pH 6.0) as the medium. After diafiltration was complete, the conjugate retentate was transferred through a 0.22 μm filter.
[0310] The conjugate was further diluted with 5 mM succinate / 0.9% saline (pH 6) to reach a target sugar concentration of approximately 0.5 mg / mL. A final 0.22 μm filtration step was completed to obtain the immunogenic conjugate.
[0311] Preferably, the conjugate obtained by the above method comprises at least 0.6 mM acetate per mM serotype 15B capsular polysaccharide, has a molecular weight of 3000-20000 kDa, and has a degree of conjugation of 2-6.
[0312] Example 2: Comprising covalent attachment to CRM 197 Characterization of immunogenic conjugates of Streptococcus pneumoniae serotype 15b capsular polysaccharide
[0313] Conjugate 1 was prepared by the method disclosed in Example 1. Conjugates 2 and 3 were prepared by similar methods using different amounts of oxidizing agent. Conjugate 4 was prepared by a similar method, except that the purified serotype 15B capsular polysaccharide was not trimmed and activated to a lower DO (higher oxidation level), and the conjugation was performed in an aqueous medium. Conjugate 5 was prepared by a similar method, except that the purified serotype 15B capsular polysaccharide was trimmed by chemical hydrolysis, and the conjugation was performed in an aqueous medium. Conjugates 6 and 7 were prepared by a similar method, except that the purified serotype 15B capsular polysaccharide was not trimmed. The resulting conjugates were characterized, and the results are summarized in Table 1.
[0314] Table 1: Capsular polysaccharide of Streptococcus pneumoniae serotype 15B - CRM 197 Conjugate
[0315]
[0316] The percentage of free polysaccharides is measured by a method that utilizes aluminum hydroxide gel to bind proteins and covalently bound sugars to be removed by centrifugation. The sample is mixed with phosphate-buffered aluminum hydroxide gel and centrifuged. The bound sugars precipitate with the gel, while the free sugars remain in the supernatant. The resulting supernatant and control samples are quantified by appropriate colorimetric assays to determine the proportion of free sugars and to confirm adequate removal of protein and recovery of sugars.
[0317] For amino acid analysis, the polysaccharide-protein sample was first hydrolyzed into its individual components using 6N hydrochloric acid (HCl) hydrolysis, heated under vacuum (160°C, 15 minutes), hydrolyzed to free amino acids. After hydrolysis, the sample was analyzed using an amino acid analyzer. The individual amino acids were separated by ion exchange chromatography using a discontinuous gradient of sodium citrate buffer with changes in temperature and flow rate. After separation, the amount of each amino acid residue was quantitatively determined using a post-column ninhydrin coupled detection system. In this system, ninhydrin is mixed with the column eluent in a post-column reactor system and the mixture enters a photometer. The reaction of ninhydrin with the eluted amino acids yields a purple compound with a maximum absorption at 570 nm. This absorbance is a linear response (function) to the amount of α-amino groups present and the reaction provides a quantitative colorimetric determination for all organic compounds with α-amino groups. In the reaction with imino acids that do not have free amino groups (such as proline and hydroxyproline), a bright yellow compound is produced and monitored at 440 nm. The peak area for each amino acid was calculated using both the 570 and 440 nm wavelength outputs.
[0318] The yield was calculated as follows: (amount of polysaccharide in the conjugate x 100) / amount of activated polysaccharide.
[0319] The conjugates produced using aqueous media (4 and 5) showed a significant loss in O-acetyl levels. The conjugates produced using native polysaccharides without molecular weight tailoring in DMSO solvent (6 and 7) did not show a loss in O-acetyl levels. However, in addition to the poor filterability characteristics, the conjugate yields were also very poor. The conjugates produced in DMSO using polysaccharides tailored by high pressure homogenization (1, 2, and 3) had higher yields and better filterability characteristics with significant preservation of O-acetyl levels. These conjugates also had very low levels of free polysaccharide.
[0320] Example 3: Opsonophagocytic activity (OPA) assay
[0321] The immunogenicity of the conjugates of the invention can be assessed using the opsonophagocytosis assay (OPA) described below.
[0322] Groups of 30 female Swiss Webster mice, 6-7 weeks old, were immunized with 0.001 µg, 0.01 µg, or 0.1 µg of the test conjugate via the subcutaneous route at week 0. Mice were boosted with the same dose of conjugate at week 3 and then bled at week 4. Serum samples at week 4 were subjected to serotype-specific OPA.
[0323] OPA is used to measure functional antibodies in murine sera specific for S. pneumoniae serotype 15B. Test sera are set up in an assay reaction that measures the ability of capsular polysaccharide-specific immunoglobulins to opsonize bacteria, trigger complement deposition, promote phagocytosis, and kill bacteria by phagocytes. The OPA titer is defined as the reciprocal dilution that results in a 50% reduction in the number of control wells relative to the absence of test serum. The OPA titer is an interpolation from two dilutions covering this 50% kill cutoff.
[0324] The OPA method was based on the method described in Hu et al., Clin Diagn Lab Immunol 2005;12(February (2)):287–95 with the following modifications. Test sera were serially diluted 2.5-fold and added to microtiter assay plates. Live serotype 15B target bacteria were added to the wells and the plates were shaken at 37°C for 30 minutes. Differentiated HL-60 cells (phagocytic cells) and rabbit serum (3–4 weeks old, Pel-Freez®, 6.25% final concentration) were added to the wells and the plates were shaken at 37°C for 45 minutes. To stop the reaction, 80 µL of 0.9% NaCl was added to all wells, mixed, and a 10 µL aliquot was transferred to a well of a MultiScreenHTS HV filter plate (Millipore®) containing 200 µL of water. The liquid was filtered through the plate under vacuum and 150 µL of HySoy medium was added to each well and filtered through. The filter plates were then incubated overnight at 37°C, 5% CO2 and subsequently fixed with Destain solution (Bio-Rad). The plates were then stained with Coomassie blue and destained once. Colonies were imaged and counted on a Cellular Technology Limited (CTL) ImmunoSpot Analyzer®. Killing curves were plotted using raw colony counts and OPA titers were calculated.
[0325] The immunogenicity of conjugates 1 and 2 has been tested according to the above assay. One additional conjugate and unconjugated native S. pneumoniae serotype 15B capsular polysaccharide (unconjugated PS) were also tested in the same assay:
[0326] Conjugate 9 was conjugated to CRM via native (i.e., non-cropped) serotype 15B capsular polysaccharide by reductive amination in aqueous solution. 197 To prepare.
[0327] The results are shown in Table 2.
[0328]
[0329] As shown in the table above, conjugates 1 and 2, when administered to mice, produced antibodies capable of opsonizing serum 15B pneumococci, triggering complement deposition, thereby promoting phagocytosis and killing of bacteria by phagocytes. In addition, despite their lower molecular weight, they also exhibited similar levels of immunogenicity relative to the untailored conjugate 9.
[0330] Example 4: Cross-functional OPA responses between serotypes 15B and 15C
[0331] Pneumococcal serogroup 15 includes four structurally related serotypes: 15A, 15B, 15C, and 15F. Serotypes 15B and 15C are indistinguishable by genotyping techniques and have similar capsular polysaccharide (PS) compositions, except that 15B-PS is an O-acetylated variant of 15C-PS. To understand whether anti-capsular PS antibodies to serotype 15B functionally cross-react with serotype 15C, 10 rabbits were vaccinated with PCV16v and PCV20v vaccines (both containing a CRM covalently linked to a PCV16v as disclosed herein). 197 Sera from before and after vaccination were tested in the OPA assay against serotype 15B and 15C target pneumococcal strains.
[0332] After immunization with the serotype 15B conjugate, 100% of the 10 rabbits from each group had an OPA response to serotype 15B. These same samples also had an OPA response to serotype 15C (Tables 3 and 4). Low OPA titers were observed in the sera before vaccination in the 15C OPA. However, the sera after vaccination had a more than 10-fold increase in GMTOPA titers compared to before vaccination, indicating that the immunogenic conjugates of the present invention induce the formation of antibodies in the OPA that are capable of killing serotypes 15B and 15C S. pneumoniae.
[0333] PCV16v is a 16-valent conjugate composition comprising glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F (16vPnC), all conjugated individually to CRMs. 197 ).
[0334] PCV20v is a 20-valent conjugate composition comprising glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F (20vPnC) (all conjugated individually to CRM 197 ).
[0335] Table 3. OPA titers against serotypes 15B and 15C in rabbit sera before and after vaccination with PCV16v
[0336]
[0337] Table 4. OPA titers against serotypes 15B and 15C in rabbit sera before and after vaccination with PCV20v
[0338]
[0339] *Titer cannot be determined due to poor killing curve Sequence Listing <110> Pfizer Inc. <120> Streptococcus pneumoniae capsular polysaccharide and its conjugate <130> PC72026A <150> US 61 / 929,561 <151> 2014-01-21 <160> 40 <170> PatentIn version 3.5 <210> 1 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> "Class A" CpG Oligonucleotides <400> 1 ggggacgacg tcgtgggggg g 21 <210> 2 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> "Class A" CpG Oligonucleotides <400> 2 ggggacgacg tcgtgggggg g 21 <210> 3 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> "Class B" CpG oligonucleotides <400> 3 tcgtcgtttt tcggtgcttt t 21 <210> 4 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> "Class B" CpG oligonucleotides <400> 4 tcgtcgtttt tcggtcgttt t 21 <210> 5 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> "Class B" CpG oligonucleotides <400> 5 tcgtcgtttt gtcgttttgt cgtt 24 <210> 6 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> "Class B" CpG oligonucleotides <400> 6 tcgtcgtttc gtcgttttgt cgtt 24 <210> 7 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> "Class B" CpG oligonucleotides <400> 7 tcgtcgtttt gtcgtttttt tcga 24 <210> 8 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> B-class oligonucleotides <400> 8 tcgtcgtttt tcggtgcttt t 21 <210> 9 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> B-class oligonucleotides <400> 9 tcgtcgtttt tcggtcgttt t 21 <210> 10 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> B-class oligonucleotides <400> 10 tcgtcgtttt gtcgttttgt cgtt 24 <210> 11 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> B-class oligonucleotides <400> 11 tcgtcgtttc gtcgttttgt cgtt 24 <210> 12 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> B-class oligonucleotides <400> 12 tcgtcgtttt gtcgtttttt tcga 24 <210> 13 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 13 tcgcgtcgtt cggcgcgcgc cg 22 <210> 14 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 14 tcgtcgacgt tcggcgcgcg ccg 23 <210> 15 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 15 tcggacgttc ggcgcgcgcc g 21 <210> 16 <211> 19 <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 16 tcggacgttc ggcgcgccg 19 <210> 17 <211> 20 <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 17 tcgcgtcgtt cggcgcgccg 20 <210> 18 <211> 20 <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 18 tcgacgttcg gcgcgcgccg 20 <210> 19 <211> 18 <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 19 tcgacgttcg gcgcgccg 18 <210> 20 <211> 18 <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 20 tcgcgtcgtt cggcgccg 18 <210> twenty one <211> twenty two <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> twenty one tcgcgacgtt cggcgcgcgc cg 22 <210> twenty two <211> twenty two <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> twenty two tcgtcgtttt cggcgcgcgc cg 22 <210> twenty three <211> twenty two <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> twenty three tcgtcgtttt cggcggccgc cg 22 <210> twenty four <211> twenty four <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> twenty four tcgtcgtttt acggcgccgt gccg 24 <210> 25 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> C-class CpG oligonucleotides <400> 25 tcgtcgtttt cggcgcgcgc cgt 23 <210> 26 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 26 tcgcgtcgtt cggcgcgcgc cg 22 <210> 27 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 27 tcgtcgacgt tcggcgcgcg ccg 23 <210> 28 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 28 tcggacgttc ggcgcgcgcc g 21 <210> 29 <211> 19 <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 29 tcggacgttc ggcgcgccg 19 <210> 30 <211> 20 <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 30 tcgcgtcgtt cggcgcgccg 20 <210> 31 <211> 20 <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 31 tcgacgttcg gcgcgcgccg 20 <210> 32 <211> 18 <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 32 tcgacgttcg gcgcgccg 18 <210> 33 <211> 18 <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 33 tcgcgtcgtt cggcgccg 18 <210> 34 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 34 tcgcgacgtt cggcgcgcgc cg 22 <210> 35 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 35 tcgtcgtttt cggcgcgcgc cg 22 <210> 36 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 36 tcgtcgtttt cggcggccgc cg 22 <210> 37 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 37 tcgtcgtttt acggcgccgt gccg 24 <210> 38 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> C-type oligonucleotides <400> 38 tcgtcgtttt cggcgcgcgc cgt 23 <210> 39 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> P-type CpG oligonucleotides <400> 39 tcgtcgacga tcggcgcgcg ccg 23 <210> 40 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> P-type CpG oligonucleotides <400> 40 tcgtcgacga tcggcgcgcg ccg 23
Claims
1. Use of an immunogenic composition in the preparation of a vaccine for preventing infection with serotype 15C Streptococcus pneumonia in a human subject, the immunogenic composition comprising an immunogenic conjugate comprising an isolated serotype 15B capsular polysaccharide of Streptococcus pneumonia covalently linked to a carrier protein, wherein the immunogenic conjugate comprises at least 0.6 mM acetate per mM serotype 15B capsular polysaccharide, wherein when administered to a human subject, the immunogenic composition induces the formation of antibodies capable of killing serotypes 15B and 15C Streptococcus pneumoniae in an opsonophagocytosis assay (OPA).
2. Use according to claim 1, wherein the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the isolated polysaccharide is at least 0.
65.
3. Use according to claim 1, wherein the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the isolated polysaccharide is at least 0.
7.
4. Use according to claim 1, wherein the ratio of mM acetate per mM serotype 15B capsular polysaccharide in the immunogenic conjugate to mM acetate per mM serotype 15B capsular polysaccharide in the isolated polysaccharide is at least 0.
8.
5. The use according to any one of claims 2 to 4, wherein the immunogenic conjugate is characterized by one of the following: wherein the immunogenic conjugate comprises less than 40% free serotype 15B capsular polysaccharide compared to the total amount of serotype 15B capsular polysaccharide; wherein the immunogenic conjugate has a molecular weight of 3000-20000 kDa; wherein the ratio of serotype 15B capsular polysaccharide to carrier protein in the conjugate is 0.4-2; and The degree of conjugation is 2-15.
6. The use according to claim 5, wherein the carrier protein is CRM 197 .
7. Use according to claim 6, wherein the immunogenic composition further comprises at least one additional antigen.
8. The use according to claim 6, wherein the immunogenic composition further comprises an adjuvant.
9. The use according to claim 7, wherein the immunogenic composition further comprises an adjuvant.
10. The use according to claim 8, wherein the adjuvant is aluminum phosphate.
11. The use according to any one of claims 1 to 4, wherein the vaccine for preventing a human subject from infection with serotype 15C pneumococcus is a vaccine for preventing pneumococcal infection associated with serotypes 15B and 15C pneumococcus in a human subject.
Citation Information
Patent Citations
Electric machine with pre-loaded roller bearing and method of manufacturing
EP1722460A1
Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228380A1
Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
US20060228381A1
Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184071A1
Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1
